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 The epidermal growth factor receptor (EGFR/ErbB1) is a receptor tyrosine kinase 
that is activated upon the formation of specific ligand-bound dimers. There are four 
homologs of EGFR in humans, and dysregulation of any of the ErbB’s is associated with 
various types of cancer. Of particular interest are ErbB3, which has an essentially 
inactive kinase domain, and ErbB2, which does not bind ligand. ErbB2 is overexpressed 
in approximately 20% of breast cancers, and heterodimers that contain ErbB2 bind their 
partner ligands more tightly, are recycled more slowly, and are more active than other 
ErbB hetero- and homodimers. ErbB2 is the preferred binding partner for the other 
ErbB’s as well, and ErbB2/3 heterodimers can evade ErbB2 targeted therapies. Given the 
clinical relevance of the EGFR family and of ErbB2 in particular, the following studies 
were pursued. 
 First, nearly full length EGFR (tEGFR) isolated in vitro was packaged into 
nanodiscs for enzymatic characterization. Previous work with tEGFR revealed interesting 
facets of wild-type and mutant tEGFR activation, but concerns that detergent solubilized 
tEGFR would not be as active as if it were in the cell cast doubt on the relevance of this 
work to physiological EGFR activity. Nanodiscs were used to isolate tEGFR in a 
membrane-like bilayer, where it was shown to be as active as when detergent solubilized. 
Nanodiscs were also used to package Smoothened, type I insulin-like growth factor 
receptor (IGF1R) and ghrelin-O-acyltransferase (GOAT) for other work, demonstrating 




 Second, ErbB2-containing heterodimers are of clear physiological relevance but 
no structural work has been done to determine how they evoke such powerful cellular 
responses. The ErbB2 extracellular domain (ECD) is structurally different from the other 
ErbB’s and thus a likely source for this different behavior. To study these ECD 
heterodimers, a tethering scheme was developed where the heavy (IgG) and light (IgK) 
chains of an Fab were each fused to one ErbB ECD by flexible glycine-serine linkers. 
Principally this work deals with ErbB2-IgK and ErbB3-IgG fusions. This scheme 
produces soluble, stable ErbB family heterodimers that bind ligand and thus are suitable 
candidates for subsequent structural studies. 
 Finally, Fab-tethered ErbB heterodimers were subjected to crystallization trials, 
small angle X-ray scattering (SAXS), and negative stain electron microscopy (EM) so 
that we might better understand the structure of an ErbB2-containing ECD heterodimer 
and how ErbB3 conformational dynamics are affected within an ErbB2/3 dimer. 
Unfortunately, exhaustive crystallization efforts did not yield crystals of sufficient quality 
for X-ray structural determination of either ErbB2/3 or ErbB2/EGFR heterodimers in the 
presence and absence of relevant ligands and therapeutic antibodies. Similarly SAXS and 
EM were unable to address our questions about ErbB3 ECD conformational dynamics. 
However, this Fab-tethering scheme will be broadly applicable to other heterodimers of 
interest and cryo-EM may yet yield the structural information we sought. 
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Chapter 1. Nanodiscs and Enzymology 
Acknowledgements 
 Zhihong Wang, Thomas Cleveland, Kwangsoo Kim, and Philip Cole were all 
critical mentors for this project. 
Introduction 
 Nanodiscs, developed by the Sligar group (Ritchie et al., 2009), were used to 
isolate purified, nearly-full length truncated epidermal growth factor receptor (tEGFR) 
for enzymatic studies. The enzymatic properties of detergent solubilized wild-type and 
cancer associated tEGFR mutants had been previously studied by the Leahy and Cole 
groups(Qiu et al., 2009)(Wang et al., 2011), but there were concerns that this system may 
not reproduce the activity of EGFR in vivo owing to solubilization of tEGFR in detergent 
micelles. I modified the general protocol for packaging single transmembrane proteins 
into MSP1E3D1 nanodiscs from Ritchie et al. and the protocols described by the Springer 
group for EGFR packaging(Mi et al., 2008) and subsequently characterized the 
enzymatic activity of tEGFR in nanodiscs. The results of this work were published in 
2013 as part of larger work describing Mig6 regulation(Wang et al., 2013), and the 
manuscript of this paper is reproduced below. 
 Type I insulin-like growth factor receptor (IGF1R) and ghrelin-O-acyltransferase 
(GOAT) were also packaged into nanodiscs for negative stain electron microscopy and 
enzymatic studies, respectively. Although IGF1R images were not ultimately used for 
structural studies and GOAT packaged in nanodiscs was inactive (as it was when 
detergent solubilized), the methods for packaging these proteins are included below. 
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 This work was published in ACS Chemical Biology in 2013. The full information 
for this paper is: 
Wang Z, Raines LL, Hooy RM, Roberson H, Leahy DJ, Cole PA. Tyrosine 
phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. 
ACS Chem Biol. 2013 Nov 15;8(11):2372-6. 
Abstract 
 Under physiological conditions, epidermal growth factor receptor (EGFR) 
tyrosine kinase activity is tightly controlled through the coordinated action of both 
positive and negative regulators. Aberrant EGFR activation occurs frequently in many 
cancer types, and the endogenous EGFR feedback inhibitor, Mig6/RALT, is more 
efficiently phosphorylated by oncogenic EGFR variants. We have utilized expressed 
protein ligation to generate semisynthetic Tyr394 phosphorylated and unphosphorylated 
forms of the Mig6 protein and shown that phosphorylation of Mig6 reduces its ability to 
inhibit purified, near full-length EGFR (tEGFR). We also demonstrate that the kinetic 
parameters of tEGFR are similar whether solubilized in detergent or reconstitutued in 
nanodisc bilayers. These findings suggest a mechanism by which EGFR and its family 
members evade negative regulation by Mig6 under pathological conditions. 
Results and Discussion 
 The epidermal growth factor receptor (EGFR) signaling cascade has been one of 
the most intensively studied signaling pathways in human biology and is the target of 
several clinically approved anticancer drugs(Lemmon & Schlessinger, 2010)(Hynes & 
Lane, 2005). EGFR and its family members HER2/Neu, HER3, and HER4 are composed 
of several domains including an extracellular growth factor- binding domain, a 
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transmembrane domain, an intracellular tyrosine kinase domain, and a C-terminal tail that 
can be autophosphorylated. Binding of EGF to EGFR stimulates its tyrosine kinase 
activity via an allosteric mechanism involving formation of an asymmetric dimer of 
intracellular kinase domains(Zhang, Gureasko, Shen, Cole, & Kuriyan, 2006). This 
asymmetric dimer juxtaposes the C-lobe of a donor kinase domain with the N-lobe of an 
acceptor (activated) kinase domain. Activating mutations of EGFR are frequently 
observed in cancer, including the common alterations L858R and exon 19 (aa746−750) 
deletion(Paez et al., 2004)(Pao et al., 2004). The protein Mig6 (RALT) was identified as 
an endogenous inhibitor of EGFR signaling(Ferby et al., 2006)(Anastasi, Baietti, Frosi, 
Alemà, & Segatto, 2007) and loss of Mig6 function can augment tumor development in 
animal models(Ferby et al., 2006). Biochemical analysis of Mig6 has revealed that a 77 
amino acid (aa) region (aa 336−412) of Mig6 is responsible for EGFR inhibition. This 77 
aa region can be further subdivided into two segments, segment 1 (aa 336−364) and 
segment 2 (aa 365−412). An X- ray crystal structure of Mig6 segment 1 complexed with 
the EGFR kinase domain shows an extended surface of interaction of segment 1 with the 
kinase C-lobe that spans a region critical for forming the asymmetric dimer with the N-
lobe of the other subunit(Zhang et al., 2007). Mig6 segment 1 thus physically obstructs 
asymmetric dimer formation, thereby inhibiting EGF-mediated EGFR activation. 
 Although the structure of Mig6 segment 2 is uncertain, the Mig6 segment 1 + 2 
polypeptide is ∼100-fold more potent than Mig6 segment 1 alone in inhibiting EGFR 
kinase activity(Zhang et al., 2007)(Wang et al., 2011). It is speculated that Mig6 segment 
2 interacts with the EGFR kinase domain along a path approaching the active site, 
thereby augmenting the affinity of the C-lobe targeted segment 1 for EGFR.8 The 
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oncogenic L858R and exon 19 (aa746−750) deletion EGFR variants appear to be 
resistant to Mig6 inhibition, presumably because their asymmetric dimer is more strongly 
favored(Wang et al., 2011).  
 Whether and how Mig6 itself is regulated has been unresolved. Mass 
spectrometry studies showed that Mig6 is tyrosine phosphorylated in cells, and 
phosphorylation of Tyr394 is enhanced in lung cancer cell lines carrying oncogenic 
L858R or exon 19 (aa 746−750) deletion mutations as well as in cells that overexpress 
HER2/Neu(Guha et al., 2008)(Wolf-Yadlin et al., 2006). Biochemical studies with 
purified proteins showed that EGFR can directly tyrosine phosphorylate Mig6(Wang et 
al., 2011). As Tyr394 is located within segment 2 of Mig6, it is conceivable that Mig6 
phosphorylation could modulate its inhibition of EGFR, which is the subject of this 
study. 
 Using in vitro kinase assays with purified, solubilized tail- truncated EGFR (aa 
25−1022, tEGFR), His6-Mig6 segment 1 + 2 appears to be phosphorylated on multiple 
Tyr residues since Y394F/Y395F Mig6 was still efficiently phosphorylated by tEGFR 
(Supplementary Figure 1). Producing a singly phosphorylated preparation of pTyr394-
Mig6 using tEGFR was thus not possible. We turned instead to protein semisynthesis and 
the method of expressed protein ligation(Muir, Sondhi, & Cole, 1998)(Szewczuk, 
Tarrant, & Cole, 2009)(Vila-Perelló & Muir, 2010)(Hackeng, Griffin, & Dawson, 1999). 
In this approach, a recombinant protein fragment containing a C- terminal thioester is 
generated by the action of a stalled intein, and this thioester is chemoselectively ligated to 
an N-Cys containing peptide to generate a standard amide bond at the ligation junction. 
After several attempts, we were unable to get adequate soluble His6-Mig6-intein fusion 
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protein production. We next investigated a GST-Mig6 (aa 336−391) intein fusion, and 
this gave acceptable production of GST-Mig6 segment 1 + 2 after ligation with N-Cys 
synthetic peptides aa 392−412 with and without phosphorylation at Tyr394 (Figure 1.1a, 
Supplementary Figure 2). We were able to obtain ∼80% conversion to ligated products 
by carrying out the reaction at 4 °C. The minor unligated GST-Mig6 may have arisen 
from nonspecific proteolysis or thioester hydrolysis that would prevent protein ligation. 
Semisynthetic proteins after purification by ion exchange and size-exclusion 
chromatographies showed a minor impurity of unligated GST-Mig6, equally represented 
in both phosphorylated and unphosphorylated preparations (Figure 1.1b). Since we 
showed that unligated GST-Mig6 (IC50 > 3 μM) is only a weak inhibitor of EGFR 
relative to ligated GST-Mig6 segment 1 + 2 (Supplementary Figure 3a), we presume the 
minor contaminant of unligated GST-Mig6 to be inconsequential. Semisynthetic GST-
Mig6 in phosphorylated and unphosphorylated forms showed the correct molecular 
weights using MALDI-TOF mass spectrometry (see Methods). The phosphorylation 
status of semisynthetic phospho-GST- Mig6 was further confirmed by Western blotting 
with anti-pTyr antibody (4G10) as shown in Figure 1.1c.  
 To analyze the effects of semisynthetic GST-Mig6 on EGFR activity, we used 
solubilized, purified tEGFR, which we have described previously(Qiu et al., 2009), as 
well as tEGFR reconstituted in membrane bilayer nanodiscs(Bayburt & Sligar, 2009). 
Nanodiscs were used to test whether detergent solubilization of tEGFR alters its 
enzymatic properties relative to a native membrane environment (Figure 1.2a). The 
steady-state kinetic parameters including apparent kcat and Km values with a synthetic 
peptide substrate of tEGFR were similar when comparing the nanodisc and detergent-
6 
 
solubilized forms (Figure 1.2b and Supplementary Figure 4). Likewise, inhibition by 
unphosphorylated semisynthetic GST-Mig6 segment 1 + 2 was similar for the nanodisc 
and solubilized tEGFRs with an IC50 of 0.3−0.4 μM (average of two independent assays) 
(Figure 1.3 and Supplementary Figure 3b). Moreover, since we replaced native aa 390−2 
(Ser-Ser- Thr) with Pro-Gly-Cys to facilitate the expressed ligation reaction for GST-
Mig6 semisynthesis (see Methods), it was important to assess the effects of these 
substitutions on the potency of Mig6 inhibition of tEGFR. Fortunately, these aa 390−2 
replacements were shown to be well-tolerated as the unphosphorylated, semisynthetic 
GST-Mig6 showed nearly identical inhibitory potency (IC50 of 0.3−0.4 μM) toward 
tEGFR as the standard recombinant His6-Mig6 segment 1 + 2 that was wild-type (WT) in 
aa 390−2 (Supplementary Figure 5). Remarkably, Tyr394-phosphorylation of GST-Mig6 
conferred a sharp reduction in inhibitory potency, with IC50 ≈ 3 μM for pTyr394-GST-
Mig6 against both solubilized and nanodisc-reconstituted tEGFR (Figure 1.3 and 
Supplementary Figure 3b). This weakened potency was comparable to that of unligated 
GST-Mig6 (aa 336−391) (Supplementary Figure 3a), underscoring that pTyr394 
phosphorylation is quite disruptive of the contributions of Mig6 segment 2 to EGFR 
inhibition. Since the segment 1 region (aa 336−364) in both unphosphorylated and 
phosphorylated GST-Mig6 is identical, and this region alone has previously been shown 
to bind to the C-lobe of EGFR kinase domain with weak inhibition against EGFR (IC50 ≈ 
100 μM)(Zhang et al., 2007),(Wang et al., 2011), it is speculated that the interaction 
between EGFR kinase domain and Mig6 segment is maintained after phosphorylation of 
Tyr394 (Figure 1.4). Interestingly, the His6-Mig6 mutant Y394E (IC50 of 0.74 μM) was 
only 2-fold less potent than unphosphorylated WT His6-Mig6 (IC50 of 0.35 μM), 
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indicating that the Glu side chain is a poor mimic of a phosphotyrosine in this case 
(Supplementary Figure 5). Thus, it would have been difficult to discern the authentic 
function of Tyr394-phosphorylation of Mig6 using mutagenesis and standard cell-based 
transfection experiments.  
 These results suggest that tyrosine kinase-catalyzed phosphorylation of Mig6 
likely represents a feedback mechanism to antagonize its inhibition of EGFR (Figure 
1.4). As noted, at least two EGFR family members when hyperactivated by mutation 
(EGFR) or elevated by increased expression (HER2/Neu) appear to target Tyr394 for 
phosphorylation in cells(Guha et al., 2008)(Wolf-Yadlin et al., 2006). Thus, Mig6 
phosphorylation provides a mechanism for these kinases to override the inhibition 
mediated by Mig6. Such an effect would augment the signaling and cell proliferative 
properties associated with the EGFR family kinases, all of which are believed to be 
susceptible to Mig6 inhibition. Thus, the activation of one family member can bolster the 
signaling from each of the others. Whether other phosphorylation sites on Mig6 also 
modulate its function will be an interesting direction for future study.  
 While the structural details of the interactions of Mig6 segment 2 with EGFR are 
not well understood, it is reasonable to speculate that segment 2 extends near the kinase 
domain active site where Tyr394 can be targeted for modification. Furthermore, we 
hypothesize that Tyr394 phosphorylation of Mig6 causes electrostatic repulsion or 
sterically clashes with the substrate ATP and/or the catalytic base aspartate. As has been 
seen with other kinases, phosphorylation of this substrate peptide motif can reduce 
affinity for the kinase, enhancing product release(Kim & Cole, 1998),(Cook, Neville, 
Vrana, Hartl, & Roskoski, 1982). Thus, it will be interesting to investigate whether 
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phosphorylation of endogenous protein inhibitors of kinases represents a general 
mechanism for overriding their inhibition. Such on/off switches may help account for the 
highly rapid cellular phosphoprotein dynamics often observed in signaling 
cascades(Qiao, Molina, Pandey, Zhang, & Cole, 2006)(Kleiman, Maiwald, Conzelmann, 
Lauffenburger, & Sorger, 2011).  
 These studies also provide a cautionary lesson for using Glu residues as mimics of 
phosphotyrosine(Xia et al., 2008),(Tamada, Farrell, & Zallen, 2012). While the negative 
charge of the Glu can nominally substitute for the anionic pTyr, its smaller size, reduced 
charge, and different shape potentially limit its utility in this regard.  
 The use of nanodisc reconstituted tEGFR shows that the key features of the kinase 
activity seen in the detergent solubilized tEGFR are recapitulated in the lipid bilayer-
embedded protein. Thus, the transmembrane helices, which have recently been suggested 
to be crucial for transmitting signaling information from the ectodomain to the 
intracellular region(Red Brewer et al., 2009),(Scheck, Lowder, Appelbaum, & Schepartz, 
2012),(Endres et al., 2013), (Adak, Yang, Macdonald-Obermann, & Pike, 2011), appear 
to be functional in the detergent solubilized systems. It will be interesting in future 
studies to determine if different lipid compositions in nanodiscs affect EGFR kinase 
activity. 
Materials and Methods 
From Wang et al. 
Plasmid Construction.  
 DNA encoding the N-terminal truncated Mig6 segment 1 + 2 (56 amino acids, 
residues 336−391) with an N- terminal GST-fusion and two mutations, S390P and 
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S391G, was subcloned into the pTYB2 vector (New England Biolads) to yield pTYB2-
GST-Mig6 plasmid. Initial semisynthetic Mig6 experiments showed that the two native 
C-terminal Ser-Ser residues of Mig6 gave poor yields of thioester product and impeded 
subsequent ligation. As also noted in the NEB brochure for IMPACT vectors, C-terminal 
Pro- Gly has been reported to be very efficient for thioester generation and expressed 
protein ligation. Plasmid pT7HT-His6-Mig6 encoding Mig6 segment 1 + 2 (77 aa, 
residues 336−412) with an N-terminal His6 tag was prepared previously and contained 
WT 390−2 residues.9 Using Quikchange mutagenesis, the mutations Y394E, Y394F, and 
Y395F were introduced into His6-Mig6 segment 1 + 2, respectively.  
Peptide Synthesis.  
 The C-terminal fragment of Mig6 (21 aa, residues 392−412) and EGFR peptide 
substrate (Biotin-RAHEEI- YHFFFAKKK-COOH) were synthesized using the standard 
Fmoc solid phase peptide synthesis strategy described previously(Tarrant et al., 2012). 
Two Mig6 peptides were synthesized, one without any post-translational modification, 
termed the unphosphorylated Mig6 peptide (CHYY- LLPERPPYLDKYEFFR), and the 
other containing a phosphorylated tyrosine residue to replace the native Tyr394, termed 
the phosphorylated Mig6 peptide (CHpYYLLPERPPYLDKYEKFFR). After C-18 
reversed phase HPLC purification, synthetic peptides were >95% pure, and structures 
were confirmed by mass spectrometry. 
Mig6 Semisynthesis.  
 Plasmid pTYB2-GST-Mig6 was trans- formed into E. coli BL21 (DE3) codon 
plus cells. Transformed cellswere cultured at 37 °C until A600 reached 0.6, and then the 
culture was incubated at 16 °C for 20 h in the presence of 500 μMIPTG to induce 
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expression of GST-Mig6 (aa 336−391)-intein-CBD fusion protein. Cell pellets were 
resuspended in lysis buffer (50 mM HEPES pH 7.4, 400 mM NaCl, 1 mM EDTA, 10% 
(v/v) glycerol, 1 tablet of protease inhibitor cocktail (Roche)) and lysed by passage 
through a French Pressure cell three times. After centrifugation at 27,000g for 30 min to 
remove cell debris, the supernatant was collected and incubated with chitin beads (New 
England Biolabs) for affinity purification. The chitin beads bound with GST-Mig6-intein-
CBD fusion protein was washed thoroughly with 1 M NaCl in washing buffer (50 mM 
HEPES pH 7.4, 1 mM EDTA, 0.1% (v/v) Triton X-100), followed by one quick wash 
with 1 M urea in washing buffer. After equilibration with three times the bead volume of 
cleavage buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1 mMEDTA), the chitin beads 
were incubated with 200 mM 2- mercaptoethane sulfonate (MESNA, Sigma-Aldrich) in 
cleavage buffer at 25 °C for 16 h to release the GST-Mig6 protein with a C-terminal 
thioester. Then, 0.5 mM phosphorylated Mig6 peptide (CHpYLLPERPPYLDKYEKFFR) 
was added to the cleaved GST-Mig6 thioester solution, and the ligation reaction was 
allowed to proceed for 48 h at 4 °C. Upon ligation reaching 80% completion as estimated 
by Commassie-stained SDS-PAGE, the semisynthetic phosphorylated GST-Mig6 seg 1 + 
2 was further purified with Mono Q ion exchange chromatography and Superdex 75 size-
exclusion chromatography. The unphosphorylated and phosphorylated forms of 
semisynthetic GST- Mig6 seg 1 + 2 were obtained using the same conditions. The 
incorporation of the phosphorylated tyrosine residue was verified with Western blot using 
the antiphosphotyrosine antibody 4G10 (Millipore). The purity and concentration of 
GST-Mig6 seg 1 + 2 were determined with SDS-PAGE Coomassie staining and Bradford 
assay using bovine serum albumin as a standard. The unligated GST- Mig6 was obtained 
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by omitting the peptide ligation step. To confirm semisynthetic GST-Mig6 with mass 
spectrometry, GST-Mig6 was further purified by reversed-phase HPLC on a C-4 column. 
The peak corresponding to pure GST-Mig6 was collected and analyzed by MALDI-TOF. 
The masses of the semisynthetic proteins were internally calibrated versus the unligated 
GST-Mig6 protein (calcd. m/z: 32,505). The unphosphorylated semisynthetic GST-Mig6 
showed m/z 35,287 (calcd. m/z: 35,283), and the phosphorylated semisynthetic GST-
Mig6 showed m/z 35,334 (calcd. m/z 35,363). The estimated standard error on these m/z 
measurements is ±50 Da.  
Packaging of EGF/tEGFR into Nanodiscs and EGFR Kinase Assays.  
 Our protocol for packaging EGF/tEGFR into nanodiscs is modified from the 
methods of the Sligar and Springer groups(Ritchie et al., 2009)(Mi et al., 2008). L-α- 
Phosphatidylcholine isolated from chicken eggs (Avanti Polar Lipids) that had been 
suspended in chloroform was dried under nitrogen to produce a film on the interior of a 
disposable borosilicate glass culture tube. Residual chloroform was removed by keeping 
this film under vacuum overnight. This lipid film was resuspended in a sodium cholate 
solution (200 mM sodium cholate, 20 mM Tris-HCl, 0.1 M NaCl, 0.5 mM EDTA, pH 
7.4) to a molar ratio of cholate to lipid of 2:1. Detergent solubilized EGF/tEGFR, 
expressed and purified as described above, and membrane scaffold protein (MSP1E3D1) 
were added to this solution to a final molar ratio of EGF/tEGFR to MSP1E3D1 to lipid to 
cholate of 1:10:1590:3180. These molar ratios resulted in packaging of EGF/tEGFR in 
∼10% of nanodiscs formed. This solution was diluted with buffer (20 mM Tris-HCl, 0.1 
M NaCl, 0.5 mM EDTA, pH 7.4) to the desired final volume for the packaging reaction 
and was incubated for 60 min at 4 °C. Then, 250 mg of Bio- Beads (BioRad), polystyrene 
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adsorbent beads that remove detergent from solution, were added per mL of reaction 
volume and incubated overnight at 4 °C. Biobeads were removed by centrifugation, as 
described previously(Ritchie et al., 2009), and the final reaction mixture was filtered and 
stored at 4 °C until use. 
Additional Nanodisc Packaging Protocols 
Smoothened 
 The packaging reaction was carried out as described as above, where 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti Polar Lipids) was used instead 
of Egg PC to a final ratio of lipid:MSP of 69.5:1. The final molar ratio of Smoothened to 
MSP1E3D1 to lipid to cholate used for this reaction was 1:10:695:1390. Smoothened was 
provided by Thomas Cleveland. The success of this reaction is shown in Figure 1.5 
IGF1R 
 The packaging reaction was carried out as described as above, where 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti Polar Lipids) was used instead 
of Egg PC to a final ratio of lipid:MSP of 75:1. MSP1D1, which should yield discs with 
diameter of 9nm, was also used instead of MSP1E3D1. The final molar ratio of IGF1R to 
MSP1D1 to lipid to cholate used for this reaction was 1:10:750:1500. IGF1R was 
provided by Jennifer Kavran. The success of this reaction is shown in Figure 1.6 
GOAT 
 MSP1E3D1 was used with DMPC at a lipid:MSP of 129:1. The final molar ratio 
of GOAT to MSP1E3D1 to lipid to cholate used for this reaction was 1:10:1290:2580. 





Figure 1.1 Preparation of the GST-Mig6 semisynthetic proteins by expressed 
protein ligation (EPL). (A) Scheme for EPL to generate the semisynthetic GST-Mig6 
segment 1 + 2 containing phosphorylated tyrosine in a full stoichiometry. The residue 
Tyr394 that can be phosphorylated by tyrosine kinases is highlighted in red. (B) 
Coomassie stained 10% SDS-PAGE of unligated and semisynthetic GST-Mig6 proteins. 
(C) The incorporation of phosphorylated Tyr394 into semisynthetic GST-Mig6 was 
verified with Western blot using the antiphosphotyrosine antibody 4G10. The same 
amount of unligated (1), unphosphorylated (2), and phosphorylated (3) Mig6 proteins 
obtained via expressed protein ligation were analyzed by 10% SDS- PAGE and probed 




Figure 1.2 Reconstitution of purified EGF/tEGFR into phospholipid bilayer 
nanodiscs. (A) WT tEGFR (aa 25−1022) purified from transiently transfected HEK293 
GnTi− cells in the presence of 0.03% dodecyl maltoside was reconstituted into nanodiscs 
assembled with membrane scaffold protein (MSP) and egg phosphatidylcholine lipids. 
The reconstituted EGF/tEGFR was subjected to 4−20% gradient SDS-PAGE and 
Coomassie staining to verify the incorporation of EGF/tEGFR into nanodiscs. BSA is 
used as a standard to quantify the protein concentrations. (B) The kinetic parameters of 
reconstituted EGF/tEGFR and EGF/tEGFR in detergent were compared. aPre- viously 
reported data. Enzymatic parameters (±SD) were calculated from duplicate experiments. 





Figure 1.3 Distinct inhibitory effects of semisynthetic unphosphorylated and 
phosphorylated GST-Mig6 on EGF/tEGFR reconstituted in nanodiscs. IC50 values of 
Mig6 were determined by quantifying the relative kinase activity of EGF/tEGFR in the 
presence of varying concentrations of unmodified and phosphorylated GST-Mig6 (0, 





Figure 1.4 Feedback regulation of EGFR activation by Mig6, an endogenous 
inhibitor of the EGFR family, is finely tuned by the phosphorylation state of Mig6. 
Mig6 inhibits EGFR by blocking the C- lobe asymmetric dimer interface. After Mig6 is 
phosphorylated by tyrosine kinases, its inhibitory potency is compromised, suggesting a 
potential strategy for cancer cells to escape the negative regulation of activated EGFR by 
Mig6. The EGFR kinase domain is depicted as blue, and segment 1 + 2 of Mig6 is 





Figure 1.5 Packaging of Smoothened into MSP1E3D1 nanodiscs with DMPC. 
Smoothened packaged nanodiscs (red trace) elute at a higher molecular weight than 





Figure 1.6 Packaging of IGF1R into MSP1D1 nanodiscs with DMPC. IGF1R (lane 1) 
survives packaging into nanodiscs after an overnight incubation at 4oC (lane 2). The 
additional band around 24kDa corresponds to the MSP1D1 protein(Ritchie et al., 2009). 
  



















Figure 1.7 Packaging of GOAT into MSP1E3D1 nanodiscs with DMPC. Purification 
of FLAG-tagged GOAT nanodiscs is seen in elution from a FLAG affinity column. Lanes 
are as labelled, with the highest molecular weight band corresponding to BSA, then to 
GOAT, then to MSP1E3D1, then to the FLAG peptide used for elution. Figure prepared 






Chapter 2. Using Fab-fusion Proteins to Isolate Heterodimers 
Acknowledgements 
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Abstract 
 Cell surface receptors frequently form or function as multimers within a cell 
membrane but fail to multimerize when soluble fragments or detergent-solubilized forms 
of the receptor are studied.  A common approach to overcome this problem is to fuse 
receptors or receptor fragments to dimeric fusion partners.  We describe here use of the 
heavy and light chain components of the antigen-binding fragment (Fab) of an antibody 
to enforce heterodimerization of the extracellular regions of the Epidermal Growth Factor 
Receptor (EGFR/ErbB) family, which naturally form functional heterodimers between 
each of the four human EGFR homologs.  We show that fusion of different ErbB 
extracellular regions to the two chains of an Fab results in formation of functional 
heterodimers and that purification of these heterodimers using an affinity tag affixed to 
the heavy chain allows purification of heterodimers from light chain-mediated 
homodimers.  Furthermore, use of an antibody directed against an epitope near the C-
termini of ErbB extracellular regions enforces a rigid structural relationship between the 





 A prerequisite for many biophysical and structural studies is isolation of a 
targeted protein or protein complex in a conformation of interest.  This task can become 
difficult when the protein or proteins of interest normally form complexes at the cell 
membrane but fail to interact when solubilized or isolated as active fragments.  A 
longstanding approach to this problem has been to enforce dimerization by expressing 
proteins fused to dimerizing partners such as the glycophorin A transmembrane 
domains(Engelman, Steitz, & Goldman, 1986),  homodimeric leucine 
zippers(Landschulz, Johnson, & McKnight, 1988), heterodimeric leucine zippers 
(O’Shea, Lumb, & Kim, 1993), and the constant (Fc) regions of antibodies  (Capon et al., 
1989) (Muraki & Honda, 2010)(Yu et al., 2013)(Dickgiesser et al., 2015). Full heavy 
chain heterodimeric proteins have also been designed using “knobs-into-holes” 
engineering(Ridgway, Presta, & Carter, 1996).  We describe here an approach to form 
heterodimers of targeted proteins using the heterodimeric antigen binding fragment (Fab) 
of antibodies. 
 We developed this system for application to the extracellular regions of member 
of the epidermal growth factor receptor (EGFR/ErbB1) family of receptor tyrosine 
kinases. Fc fusions have been used to study many facets of their EGFR homodimer 
activation(Jones, Akita, & Sliwkowski, 1999)(Burgess et al., 2008)(Bessman, Bagchi, 
Ferguson, & Lemmon, 2014), but all possible heterodimers of the 4 human ErbB 
homologs (EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4) appear to form 
and possess unique signaling properties (Holbro & Hynes, 2004). Dysregulation of these 
proteins is implicated in a variety of cancers, and many are the target of monoclonal 
antibody therapies and small molecule inhibitors. ErbB2 is overexpressed in 
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approximately 20% of breast cancers and is also implicated in cancers of the colon and 
lung(Holbro & Hynes, 2004), and heterodimerization with ErbB2 increases the affinity of 
its partners for their ligands(Jones et al., 1999), decreases receptor internalization(Tzahar 
et al., 1996), and ErbB2/ErbB3 heterodimers escape ErbB2 targeted therapy(Sergina et 
al., 2007) and are considered the most oncogenic pairing within this family(Holbro & 
Hynes, 2004). Although ErbB2 heterodimerization has clear functional and clinical 
implications, ErbB2-containing heterodimers must differ structurally from other ErbB 
family hetero- and homodimers(Alvarado, Klein, & Lemmon, 2010)(Liu et al., 2012), but 
the precise nature of these structural differences and how they influence function remain 
unclear. The kinase domains of these four homologs all adopt canonical kinase folds 
although the ErbB3 kinase domain lacks functional kinase activity (Zhang et al., 
2006)(Holbro & Hynes, 2004), but isolated ECDs of ErbB2 and other ErbB homologs 
fail to dimerize in solutions up to concentrations as high as 0.1mM(Ferguson, Darling, 
Mohan, Macatee, & Lemmon, 2000).  As numerous studies indicate highly active ErbB2-
containing ErbB heterodimers, we designed an Fab-driven heterodimerization system to 
allow isolation and study of ErbB2/ErbB3 extracellular domain heterodimers. 
Results and Discussion 
 Figure 1 diagrams our fusion scheme, where two ErbB extracellular regions 
(referred to hereafter as Protein A and Protein B to reflect the generality of this approach) 
are fused to either the heavy (IgG) or light chains (IgK) of an Fab. The IgG and IgK 
fusion proteins are then co-transfected into mammalian cells where they were secreted 
together and are subsequently purified. We used Fab 1479, an anti-ErbB4 antibody which 
is being developed as a potential breast cancer treatment(Hollmén, Määttä, Bald, 
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Sliwkowski, & Elenius, 2009), although many Fabs could be used.  The 1479 antibody 
was chosen this case because it is known to bind to an epitope near the C-terminus of the 
ErbB4 extracellular region that can be transplanted into other ErbBs.  By binding to this 
epitope, the Fab fusion partner will thus adopt a relatively rigid orientation relative to the 
ErbB heterodimer, which may enhance the success of attempts to crystallize expressed 
heterodimers. We also mutated the cysteine residues that form a disulfide bond between 
the IgG-IgK chains to allow visualization of dimer subunits when using nonreducing SDS 
PAGE. Flexible glycine-serine linkers(Ladurner & Fersht, 1997) were inserted between 
each protein of interest and either the heavy or light chain of Fab 1479.  The length of the 
linkers were determined by modeling the distance between the ErbB C-termini and Fab 
N-termini based on crystal structures of 1479 bound to ErbB4(Hollmén et al., 2009) (Liu 
et al) and an ErbB4 homodimer(Liu et al., 2012) (Liu et al).  As noted, we transplanted 
the 1479 epitope to the C-terminus of Protein 1 (in this case, the ErbB3 extracellular 
domain) to ensure a rigid association between these partners for subsequent 
crystallization trials. We used surface plasmon resonance (SPR) to see that our linkers, as 
designed, did not inhibit ligand binding. In fact, binding of ErbB2/ErbB3 heterodimers to 
the ligand Neuregulin was tighter than binding of the ErbB3 extracellular region alone to 
Neuregulin (191nM vs. 267nM).  The affinity of expressed ErbB2/ErbB3 heterodimers 
for ligand was not significantly changed with longer linker length (191nM vs. 178nM), 
which implies that binding of ErbB2/ErbB3 heterodimers to Neuregulin was not 
constrained by glycine-serine linkers that are too short.  Testing heterodimer activity as a 
function of linker length provides a general approach to ensuring optimal linker length 
depending on the system being studied.  
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 Figure 2A depicts the fusion partner scheme that ultimately produced the highest 
yields of active, purified heterodimers.  Both expressed chains had human growth 
hormone (hGH) fused to their N-terminus of a protein to aid expression in mammalian 
cell culture as well as detection (Leahy, Dann, Longo, Perman, & Ramyar, 2000).. The 
cDNA for interleukin-2 (IL-2) was placed C-terminal to the hGH tag for the IgG fusion 
to add 16kDa in molecular weight and allow visualization of otherwise similarly sized 
subunits using nonreducing SDS PAGE.   We observed the presence of IgK homodimers, 
which were removed by Ni-NTA purification specific for a tag on the heavy-chain 
subunit, as seen in Figure 2B. Fab region heavy chains do not productively 
homodimerize(Schoonjans et al., 2000) and we see no evidence of IgG-Fab homodimers 
in our system (Figure 2B). IgG and IgK fusions co-migrate across affinity, anion 
exchange, and gel filtration chromatography at 1:1 stoichiometry, and can be effectively 
deglycosylated with PNGaseF.  The fusion partners are also effectively removed with 
PreScission/3C protease (Figure 2C). Final yields for ErbB2-containing heterodimers 
were approximately 100 – 200ug/L of mammalian cells, and purified heterodimers elute 
as a monodisperse peak by gel filtration. Sufficient amounts of ErbB2/ErbB3 
heterodimers were purified for X-ray crystallography trials, small angle x-ray scattering, 
and electron microscopy. 
 This Fab-driven heterodimerization scheme is easily adaptable to other proteins, 
and the epitope recognized by the Fab could be omitted or included as fits the 
experimental application. Fab-driven heterodimers expand on previously successful Fc 
fusions and represent a useful way to isolate soluble heterodimers of interest. 




 The vectors developed for IgG and IgK fusion protein purification are pSGHP0 
and pHSP0, respectively. pSGHP0 is modified from pSGHV0, described 
previously(Leahy et al., 2000), to include the cDNA for IL-2 3’ to the gene for hGH and 
5’ to an octahistidine tag, followed by a 3C Protease/PreScission cut site. pHSP0 is 
similarly modified, with a streptactin binding protein (SBP) tag in place of IL-2. XbaI 
and NotI-HF (NEB) were used to introduce IgG and IgK fusion proteins into both 
vectors. 
Mammalian cell transfection 
 HEK293 and GnTi-, a cell line useful for crystallization trials because all sites 
that are normally subject to N-glycosylation are glycosylated but not fully processed due 
to lack of N-acetylglucosaminyltransferase I(Chang et al., 2007), cells were maintained in 
suspension as described previously(Longo, Kavran, Kim, & Leahy, 2013) Mammalian 
cells were transiently transfected with high quality (OD260/280 = 1.88 – 1.92; 
OD260/230 = 2.1 – 2.2) purified DNA and polyethylene imine (PEI) at a 1:3 ratio, with 
200ug of heterodimer vector introduced per liter of mammalian cells. Optimum co-
transfection ratios of each IgG and IgK fusion were determined in small scale adherent 
culture before purification in large scale suspension. ErbB2/ErbB3 heterodimers were 
produced using 100ug of each construct per liter of cells, and equal DNA co-transfection 
gave optimum expression levels of all heterodimer constructs tested. 24 hours later 
transiently transfected cells were diluted 1:3 and grown in hybridoma media 




 Media from transiently transfected mammalian cells was spun at 1000g for five 
minutes then sterile filtered (0.22µm). Sodium azide was added to 1mM in filtered media. 
All subsequent purification steps were performed at 4oC. A CentramateTM tangential flow 
filtration cassette (Pall) was used to concentrate media and buffer exchange into buffer A 
(20mM Tris 8, 1M NaCl). Five milliliters of Ni-NTA were allowed to bind in batch with 
concentrated heterodimers overnight. This solution was applied to a gravity column so 
that the Ni-NTA resin could be washed four times with 50mL of buffer A supplemented 
with 1) 1M urea, 2) 0.75% TX-100, 3) 1M Urea, and 4) 0.75% TX-100. These washes 
were followed by a 100mL wash of buffer A and elution with 60mL of buffer A with 
250mM imidizaole. Nickel eluate was diluted to 1L in buffer A and applied to 5mL of 
freshly equilibrated Ni-NTA resin to batch bind overnight. This second batch of resin was 
applied to a gravity column and washed with 300mL of buffer A. Five milliliter fractions 
of heterodimers were eluted in 60mL of buffer A with 250mM imidazole. Fractions 
containing heterodimers were detagged and deglycosylated, as appropriate, with excess 
3C Protease/PreScission and PNGaseF, respectively. Samples were dialyzed against four 
liters of 20mM Tris 7, 150mM NaCl, 1mM EDTA for two days or until cleavage was 
complete. Afterwards, samples were dialyzed against four liters of buffer A for at least 
one hour before application to a 5mL Ni Hitrap column (GE). The majority of untagged 
heterodimer did not bind this column and was collected in the flow-through, although 
some also came off with 250mM imidazole washes. Fractions containing heterodimers 
were dialyzed against four liters of 20mM Tris 8, 50mM NaCl overnight before 
application to a HiTrap Q column (GE). Heterodimers were eluted using buffer A, then 
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concentrated and loaded onto a G200 26/60 gel filtration column equilibrated in 5mM 
Tris 7.5, 150mM NaCl. Heterodimers were then concentrated as appropriate. 
SPR 
 SPR binding experiments were performed using a Biacore 3000 instrument at 
25°C. Neuregulin was immobilized in pH 5.0 acetate buffer, with ~100 response units 
(RUs) immobilized. ErbB3 extracellular domain or Fab-driven heterodimers were 
injected in serial 3-fold dilutions in 25 mM HEPES, pH 8.0, containing 150 mM NaCl, 
3.4 mM EDTA, and 0.005% Nonidet-P20. A flow rate of 5 μl/min was used for 10 
minutes, which was sufficient to reach a stable RU equilibrium even at the lowest 
concentrations tested. Binding for each injection was calculated by subtracting the 
baseline RU reading from the RU response at 10 minutes post-injection. KD values for 
binding of receptor variants to these surfaces were determined by fitting the equilibrium 
responses over a range of concentrations to binding models in GraphPad Prism 5.0. For 
ErbB3 extracellular domain binding to the neuregulin sensor chip, the data were 
adequately fit by a single-site Langmuir binding equation. For heterodimeric variants, 
better fits were achieved with a binding model specifying one specific binding site plus a 
non-saturable, weak, non-specific binding component. Between injections, surfaces were 
regenerated using 1 minute injections of 10 mM sodium acetate, pH 5.0, containing 1 M 






Figure 2.1 Fab-driven heterodimers. A) Cartoon representation of Fab-driven 
heterodimers, where the heavy chain (IgG) of Fab 1479 is fused by a flexible glycine-
serine linker (dotted line) to a protein of interest, hereafter referred to as Protein 1. The 
epitope recognized by Fab 1479 is denoted by a white star, and is introduced to the C-
terminus of Protein 1. This creates a rigid association between the IgG and Protein 1 to 
aid crystallization efforts. The light chain (IgK) of 1479 is similarly fused with a flexible 
glycine-serine linker to Protein 2. 
B) Diagram representation of Fab-driven heterodimer proteins to be co-transfected in 
mammalian cells and purified as in Figure 2. The gene for human growth hormone (hGH) 
is introduced to the N-terminus of Fab fusion proteins as previously described (Leahy et 
al., 2000) to increase expression in mammalian cells. Protein 1 and Protein 2 designed for 
pilot studies (ErbB3-IgG and ErbB2-IgK) are of nearly identical molecular weight, and 
so the cDNA for interleukin-2 (IL-2) was introduced to enable easy differentiation of 
each fusion partner by SDS-PAGE. An octahistidine tag was added to only the IgG 
fusion partner, as IgG Fab homodimers are not a contaminant of concern(Schoonjans et 






Figure 2.2 Purification of Fab-driven heterodimers. A) IgG and IgK fusion proteins 
co-migrate at stoichiometric levels over affinity purification, anion exchange, and gel 
filtration chromatography.  The bands corresponding to IgG and IgK fusions are shown 
by dark and light gray arrows, respectively. All gels shown are representative of multiple 
heterodimer purifications. Contaminating IgK homodimers are removed through Ni-NTA 
purification, as seen in the flow-through and wash fractions. 
B) I IgG and IgK fusion proteins are effectively deglycosylated and detagged by 
PNGaseF and 3C Protease treatment, respectively. Purified Fab-driven heterodimers elute 
as a monodisperse peak over gel filtration. Shown here is a representative gel filtration 
trace in the presence of ligand and an additional therapeutic antibody. Final yields were 





Figure 2.3. Binding of Fab-driven heterodimers to neuregulin. SPR data are shown 
for soluble ErbB3 extracellular domain (●), Fab-driven ErbB2/3 dimers as originally 
designed (▲), and ErbB2/3 dimers with longer glycine-serine linkers (■). Curves were fit 
with the assumption that one site bound ligand specifically, while another site bound non-
specifically (as only one competent binding site is present within each heterodimer and 
sErbB3). The Kd for each of these dimers for neuregulin is 267nM, 191nM, and 178nM, 
respectively. Linker length did not significantly alter ligand binding, demonstrating that 







Chapter 3. Heterodimer Crystallography, SAXS, and EM 
Acknowledgements 
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Abstract 
 The “deaf and the dumb” members of the ErbB family of receptor tyrosine 
kinases, namely ErbB2 which does not respond to ligand and ErbB3 which has an 
essentially inactive kinase domain(Citri, Skaria, & Yarden, 2003), are considered the 
most oncogenic heterodimer pair within the ErbB family(Holbro & Hynes, 2004). 
Despite the availability of high resolution structures of the ErbB extracellular and 
intracellular domains, it is still unclear how heterodimerization with ErbB2 evokes such 
exaggerated responses. Although the extracellular domains of liganded ErbB’s look 
similar to the ErbB2 ECD, a 30o domain rotation prevents ErbB2-containing 
heterodimers from adopting the same conformation as other ErbB ECD homodimers. 
(Figure 3.1). The Fab-heterodimerization scheme described in Chapter 2 was used to 
purify ErbB2/3 heterodimers as well as other physiologically relevant ErbB heterodimers 
for structural studies. Unfortunately crystallization trials were unsuccessful, as were small 
angle X-ray scattering (SAXS) and negative stain electron microscopy (EM) analyses of 
ErbB2/3 heterodimers. Initial designs for studying the energetics of ligand binding to 
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various EGFR-containing heterodimers by isothermal titration calorimetry (ITC) were 
hindered by insufficient protein yields. These preliminary studies are described below. 
Introduction 
 The Fab-driven heterodimerization scheme described in Chapter 2 was designed 
specifically for the crystallization and subsequent structural determination of an ErbB2-
containing heterodimer. The ErbB2/3 heterodimer is considered the most relevant to 
human cancers(Holbro & Hynes, 2004) and current high resolution structures do not 
resolve how ErbB2-containing heterodimers mediate their exaggerated effects on cell 
growth and proliferation (Figure 3.1). Cursory surface plasmon resonance experiments 
showed that the binding affinity of ErbB2/3 heterodimers for neuregulin was tighter than 
for the soluble ErbB3 ECD alone, as predicted by previous work(Jones et al., 1999), and 
was not significantly different if the glycine-serine linkers between ErbB ECDs and their 
IgK/IgG fusion partners were lengthened (Figure 2.3, Table 3.1). This led us to believe 
that there was nothing inherently amiss about our Fab-driven ErbB family heterodimers 
and that crystallization trials were performed with proteins that, if crystallized, would be 
useful approximations of ErbB family heterodimers in vivo. 
 Exhaustive crystallization trials were conducted for ErbB2/3 heterodimers in the 
presence and absence of ligands and relevant therapeutic antibodies. Although small 
crystals were obtained in the presence of neuregulin (Figure 3.3), we were unable to 
optimize them to diffract to a sufficient resolution for structural determination. Additional 
efforts, summarized in Table 3.2, included setting trays with ErbB2/ EGFR and with 
ErbB2/3 heterodimers with longer glycine-serine linkers. In total, more than 3,600 and 
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1,100 conditions were tested for crystallization of ErbB2/3 and ErbB2/EGFR 
heterodimers, respectively.  
 Putative ErbB2/3 microcrystals were initially screened by Tom Murray for use 
with a microbeam synchrotron source, but additional studies were not pursued as they did 
not detectably diffract X-rays. ErbB2/4 and asymmetric EGFR heterodimers, where one 
EGFR can bind ligand and the other EGFR cannot, were similarly prepared at small scale 
with later crystallization trials in mind. These were not ultimately pursued in large scale 
because the ErbB2/4 heterodimer is less physiologically relevant than the ErbB2/3 and 
ErbB2/EGFR dimers(Holbro & Hynes, 2004), and initial purification efforts of 
asymmetric EGFR produced low yields (~20ug/L. Focus shifted towards using small 
angle X-ray scattering (SAXS) and negative stain electron microscopy (EM) to capitalize 
on our purified ErbB2/3. 
 We attempted to use SAXS and EM to determine whether the ErbB3 ECD favors 
the tethered or extended conformation in the absence of ligand, as illustrated in Figure 
3.4. We pursued this as a logical follow-up to work done by the Lemmon laboratory, 
where Fc-driven EGFR homodimers were purified and studied with these 
techniques(Bessman et al., 2014). In this report, despite predicted particle dimensions 
nearing the detection limit for negative stain EM and SAXS (Figure 3.4), a clear 
difference was visible between well-ordered ligated EGFR homodimers compared to 
unliganded dimers. We thus predicted that we could obtain similar resolution data to 
address our question. 
 Unfortunately, we were unsuccessful. The differences in SAXS envelopes from 
the ErbB3 extended and tethered models were very small (Table 3.3) and no discernible 
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difference in model fit can be seen from final SAXS envelopes produced using data from 
the SAXS source at the University of Pennsylvania (Rigaku S-MAX3000 pinhole camera 
system with a Rigaku 007HF rotating anode source and a Rigaku 300 mm wire grid ASM 
DTR 200 detector) (Figure 3.5). Although the envelopes obtained are of the right size and 
contain the predicted curvature expected from 1479 Fab binding, data collected in the 
presence or absence of ligand were essentially indistinguishable. 
 This observation may be because the ErbB3 ECD is extended in the absence of 
ligand, but we were unable to resolve this possibility. We attempted to obtain a control 
envelope where one partner was extended (ErbB2) and the other were tethered by binding 
the Fab of cetuximab (Erbitux©), an antibody that keeps the EGFR ECD in a tethered 
conformation, to ErbB2/EGFR homodimers. However, we did not see cetuximab binding 
to these heterodimers and thus could not compare our data to this reference. 
 Similarly, negative stain EM class averages revealed particles of roughly the 
expected size and shape but provided inconclusive information. 2-D projections were 
generated from both the ErbB3 extended and tethered models and compared to class 
averages. To reduce bias during model fitting, all 2-D projections were compared to all 
class averages in the presence and absence of neuregulin. The final results of these 
comparisons are summarized in Table 3.4, and a representative comparison of class 
averages to 2-D projections is shown in Figure 3.6. These comparisons were performed 
by Ernesto Arias-Palomo, a member of the lab of James Berger who has extensive EM 
experience. 
 If our data could accurately distinguish whether ErbB3 is extended or tethered 
within our ErbB2/3 heterodimers, we would expect our samples collected in an excess of 
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ligand to adopt almost exclusively an extended model conformation. However, our data 
do not show clearly show this conformation, and thus we cannot draw any conclusions 
from this work at this time. 
 Bessman et al. also used a GE MicroCal ITC200 to perform isothermal titration 
calorimetry (ITC) to study the relationship between ligand binding and dimerization 
within tethered EGFR homodimer. A logical continuation was to expand this work to 
cover EGFR family heterodimers, where the following titrations would be performed: 
1. EGFR/EGFR with 1479 epitope + EGF 
2. EGFR/EGFR without epitope + EGF 
3. Asymmetric EGFR + EGF  
4. EGFR/ErbB2 + EGF 
5. ErbB3/ErbB2 + neuregulin 
6. ErbB3 + neuregulin 
Titrations 1 and 2 would have shown if the rigid association of Fab-driven heterodimers 
containing the 1479 epitope affected ligand binding and if we could reproduce the work 
from Bessman et al. Titration 3 would have mimicked the singly-ligated Drosophila 
EGFR homodimer. Titration 4 would have demonstrated the effects of ErbB2 on ligand 
binding, Titration 5 would have compared ErbB2’s effects of EGFR to those on ErbB3, 
and the binding of ErbB3 would have served as a control. 
 In their work, they used roughly 10µM of protein in 200µL of a reaction cell per 
titration. Under similar reaction conditions, approximately 0.5mg of purified Fab-driven 
heterodimer would be needed per titration. While this is a large amount of protein given 
optimum yields of 200µg/L of mammalian cells for ErbB2/3 purification, it would have 
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been feasible if final yields of other EGFR family heterodimers were similar. However, 
the necessary heterodimers were not highly expressed in either mammalian or insect cell 
lines. Insufficient final yields of EGFR homodimers containing the 1479 epitope 
prevented this necessary titration from being completed and thus negated the utility of 
any further titrations. 
Materials and Methods 
Crystallization Trials 
 Fab-driven heterodimers were purified as described in Chapter 2 and Appendix II, 
with ligands and relevant therapeutic antibodies added as appropriate, and concentrated to 
1 – 5mg/mL. A Mosquito liquid handling robot (TTP Labtech) was used for 96-well 
screening using standard crystallization kits. Promising conditions were followed up in 
24-well plates.  
Small Angle X-ray Scattering (SAXS) 
 X-ray scattering data were collected at three concentrations of ErbB2/3 
heterodimer (typically 2, 4, and 6mg/mL; or 1, 3, and 5mg/mL) and radially averaged and 
initially processed using SAXSgui. The ATSAS program suite was used to further 
process SAXS data(Svergun & Koch, 2003). PRIMUS was used to assess data quality 
and determine radius of gyration (Rg) values(Konarev, Volkov, Sokolova, Koch, & 
Svergun, 2003), GNOM was used to determine maximum interatomic distance (Dmax) 
values from P(r) curves(Svergun, 1992), DAMMIN(Svergun, 1999) and 
DAMMIF(Franke & Svergun, 2009) were used to generate models from SAXS data that 
were aligned with DAMAVER(Volkov & Svergun, 2003). Expected Rg and Dmax values 
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for ErbB3 extended and tethered heterodimer models were generated in 
Crysol(Barberato, Koch, Molecular, & Outstation, 1995). 
Negative Stain Electron Microscopy (EM) 
 Staining conditions were modeled after those used in Bessman et al. and grids 
were set by Dewight Williams, Director of Electron Microscopy Resources at the 
Biochemistry and Biophysics Department at University of Pennsylvania. Raw grid 
images were visualized using Gatan Digital Micrograph (Gatan). Particle picking was 
done manually using the EMAN2 software package(Tang et al., 2007) and class averages 
were generated by Dewight Williams using SPIDER(Shaikh et al., 2008). 2-D projections 
were generated in EMAN2 from volume models created in Chimera(Pettersen et al., 




 Exhaustive crystallization trials produced small (<60µm) crystals of ErbB2/3 
heterodimers in the presence of neuregulin (Figure 3.3) that could not be improved and 
did not diffract X-rays. Useful crystals were not obtained for ErbB2/3 heterodimers in the 
presence or absence of relevant therapeutic antibodies, nor were crystals obtained for 
ErbB2/EGFR heterodimers (Table 3.2). 
Small Angle X-ray Scattering (SAXS) 
 Although final SAXS envelopes were roughly consistent with predicted models 
for ErbB2/3 heterodimers, no conclusive statement about ErbB3 ECD domain dynamics 
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within the context of a heterodimer can be made (Figure 3.5). This is consistent 
regardless of light source, and thus roughly the quality of data, used. 
Negative Stain Electron Microscopy (EM) 
 Similar to the final SAXS envelopes, select negative stain class averages roughly 
correspond to the predicted size and shape of ErbB2/3 heterodimers but do not provide 
interpretable structural information (Figure 3.6). 
Proposed Isothermal Titration Calorimetry 
 The heterodimers needed for titrations 1 – 6 were not expressed highly from 
mammalian nor insect cell lines. EGFR homodimers containing the 1479 epitope could 
not be purified at greater than 10ug/L final yields. Thus, these experiments could not be 
performed. 
Discussion 
 Although our biophysical and structural studies of ErbB2/3 heterodimers could 
not be completed (crystallization, ITC) or were inconclusive (SAXS, EM), the 
heterodimerization method described in Chapter 2 may be broadly applicable to other 
systems. It is possible that further negative stain or Cryo-EM may address whether the 





Figure 3.1 Key structural differences must be accommodated in ErbB2-containing 
heterodimers. A) Ligand binding induces ECD conformational change in hEGFR, 
ErbB3, and ErbB4. C) ErbB2 resembles ErbB4 bound to neuregulin (NRG), but has ~30o 
relative domain rotation. Structures from (Burgess et al., 2008), (Liu et al., 2012), and 





Figure 3.2 ErbB2/3 Crystals. Optimum ErbB2/3 heterodimer crystals formed in the 
presence of neuregulin. Despite extensive efforts crystals could not be improved. Scale 





Figure 3.3 Model for SAXS and EM studies. After unsuccessful crystallization efforts, 
we pursued small angle x-ray scattering (SAXS) and negative stain electron microscopy 
(EM) to determine if the ErbB3 ECD favors a tethered or extended conformation within 
an ErbB2/3 heterodimer. The above is a representation of this research question. This 
structural model is based on the crystal structures of singly-ligated Drosophila 
EGFR(Alvarado et al., 2010) and the extracellular domains of ErbB3(Ferguson et al., 





Figure 3.4 Predicted dimensions of an Fab-tethered ErbB2/3 heterodimer where 
ErbB3 is extended. This structural model is based on the crystal structures of singly-
ligated Drosophila EGFR(Alvarado et al., 2010) and the extracellular domains of 





Figure 3.5 Final SAXS envelopes. These envelopes were generated from data obtained 
from the SAXS source at the University of Pennsylvania in the absence of ligand.  
Similar envelopes were obtained from the Rigaku BioSAXS-2000. Neither envelope 
conclusively fits either the ErbB3 extended or tethered models, consistent with SAXS 





Figure 3.6 Representative EM class averages and 2-D model projections. Selected 
class averages from ErbB2/3 without ligand (left) vs 2-D projections of ErbB3 extended 
model (right). Similar class averages were seen in samples with ligand, and neither set of 
class averages agrees significantly with the ErbB3 extended or tethered models. 







 Binding Affinity for NRG Binding Affinity from  
Jones et al, 1999 
 05/06/2013 03/15/2014 
ErbB3 ECD 152nM 267nM 1 – 100nM 
ErbB2 + 4 GS 
ErbB3 + 6 GS 
59nM 191nM <1nM (no linker) 
ErbB2 + 6 GS 
ErbB3 + 8 GS 
- 178nM <1nM (no linker) 
 
Table 3.1 Neuregulin binding to ErbB2/3 heterodimers by SPR. Assays performed by 
Nick Bessman on different dates, as indicated below. Binding affinity values from the 
Sliwkowski groups are included for comparison(Jones et al., 1999). Surface plasmon 



























Yes Yes Yes 




















Yes - - - 
 
Table 3.2 Summary of Crystallization Efforts. Greater than 3,600 crystallization 
conditions of antibody driven HER2/HER3 heterodimers, including combinations of all 
relevant therapeutic antibodies and ligands available to the Leahy laboratory, and 
screening of approximately 1,100 conditions for crystallization of HER2/EGFR 
heterodimers did not produce crystals that diffracted to a sufficient resolution for 





Source Penn Rigaku 
 Alone with NRG Alone with NRG 
Rg 50 +/- 4.72 Å 65 +/- 13.3 Å 70 Å 60 Å 
Dmax 200 Å 200 Å 250 Å 220 Å 
 Crysol Predicted 
 Tethered Extended 
Rg 55 Å 60 Å 
Dmax 196 Å 196 Å 
 
Table 3.3 Summary of Small Angle X-Ray Scattering (SAXS) Parameters. Expected 
differences between envelopes where the ErbB3 extracellular domain is extended and 
tethered were small, and comparing data collected from the SAXS source at the 
University of Pennsylvania (“Penn”) and from the Rigaku BioSAXS-2000 (“Rigaku”) 
could not resolve if one model better fit our data. SAXS envelopes corresponding to this 










Both Equally Neither Fits 
With NRG 9 /20 6 /20 3 /20 2 /20 
Without NRG 9 /20 8 /20 3 /20 0 /20 
 
Table 3.4 Summary of Electron Microscopy Efforts. Attempts to fit 2-D projections of 
the ErbB3 extended nor ErbB3 tethered ErbB2-containing heterodimer models (Figure 
3.2) to class averages obtained from electron stain microscopy were unsuccessful.  
Sample class averages compared to 2-D projections are in Figure 3.5. EM grids set with 
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1.1 DNA Catalog – List of Constructs 
“Raines Box 1” also called Leahy Lab DNA Stock Box 14 
 
Vector s  Insert   Cut In With  Location 
pSGHRP0  -   -   14/Raines Box 1, 2 
pHSP0   -   -   Raines Box 1, 3 
pSGHV0  -   -   Raines Box 1, 4 
pSSXm  -   -   Raines Box 1, 5 
pCDNA 3.1  -   -   Raines Box 1, 6 
pFastBac HBM -   -   Raines Box 1, 7 
Fab-driven Heterodimer Fusion Proteins 
Vector   Insert   Cut In With  Location 
pSGHRP0  H1*G   “   Raines Box 1, 32 
   H3*G   5’ XbaI/3’ NotI Raines Box 1, 33  
   H4G   “   Raines Box 1, 34 
   EG   “   Raines Box 1, 35 
   H3*G + 8 gs     Raines Box 1, 43 
pHSP0   H2K   5’ XbaI/3’ NotI Raines Box 1, 52 
   LK   “   Raines Box 1, 53 
   EK   “   Raines Box 1, 54 
   H4G   “   Raines Box 1, 55 
   H2K + 6 gs     Raines Box 1, 62 
pSGHP1  H1*G   5’ XbaI/3’ NotI Raines Box 1, 72 
   H2K   “   Raines Box 1, 73 
   H4G   “   Raines Box 1, 74-5 
pSSX    EG   5’ XbaI/3’ NotI Raines Box 1, 59 
   H3wtG  “   Raines Box 1, 69 
Ligands 
Vector   Insert   Cut In With  Location 
pET32a  NRG1β  ?   Raines Box 1, 17 
   NRGβ56  ?   Raines Box 1, 18 
pT7HT  hEGF   ?   Raines Box 1, 19 
Other Proteins 
Vector   Insert   Cut In With  Location 
pSSX   IGF1R   ?   Raines Box 1, 79 
pLEXm  WT tEGFR  5’NotI/3’XhoI  Raines Box 1, 82 
pLEXm  delEA tEGFR  “   Raines Box 1, 83-4 
pLEXm  L858R tEGFR  “   Raines Box 1, 85-6 
pLEXm  FL EGFR with kinase mutant   Raines Box 1, 87-8 
pMal3CBN  IL2 cDNA BALB/C 5' BamHI/3' NotI Raines Box 1, 8 
pMal3CBN  IL2 cDNA RF  5' BamHI/3' NotI Raines Box 1, 9 
???   “ErbB4 Ab N-term” ?   Raines Box 1, 10 
 MSP1D1  http://www.addgene.org/20061/ Raines Box 1, 92-93 
 MSP1E3D1  http://www.addgene.org/20066/ Raines Box 1, 94-95 




DNA Catalog – Sequence Information 
 
Empty Vector: pHSP0 
Derived from: pSGHV0 for mammalian expression  
Tags introduced using: 5’XhoI/3’BamHI (relevant sites underlined) 
Tags: hGH gene – SBP tag – 3C Protease cleavage site 

















































Description: ErbB2 ECD + linker + Fab 1479 IgK 
Underline: linker; Bold: IgK 









































































































Description: EGFR ECD with D355A, can’t bind ligand + linker + Fab 1479 IgK 
Italic: linker; Bold: IgK 











































































































Description: EGFR ECD + linker + Fab 1479 IgK 
Underline: linker; Bold: IgK 










































































































Derived from: pSGHV0 for mammalian expression 
Tags introduced using: 5’XhoI/3’BamHI (relevant sites underlined) 
Tags: hGH gene – IL2 RF cDNA – 8x His tag – 3C Protease cleavage site 























































Description: ErbB3 ECD with Fab epitope + linker + Fab 1479 IgG 
Underline: linker; Bold: IgG 












































































































Description: EGFR ECD with Fab epitope + linker + Fab 1479 IgG 
Underline: linker; Bold: IgG 












































































































Description: ErbB4 ECD with Fab epitope + linker + Fab 1479 IgG 
*** note: Fab 1479 epitope from ErbB4, no need to mutate*** 
Underline: linker; Bold: IgG 













































































































Description: WT EGFR ECD + linker + Fab 1479 IgG 
Underline: linker; Bold: IgG 































Vector + Insert: pSGHRP0 + EG 
Description: WT EGFR ECD + linker + Fab 1479 IgG 

















































































*Never used for Fab-fusion purifications* 
Derived from: pSGHV0 for mammalian expression 
*** Same as pSGHRP0 except using BALB/C IL2*** 
Tags introduced using: 5’XhoI/3’BamHI (relevant sites underlined) 
Tags: hGH gene – IL2 RF cDNA – 8x His tag – 3C Protease cleavage site 





















































*Never used for Fab-fusion purifications* 
Derived from: pSGHV0 for mammalian expression  
Tags introduced using: 5’XhoI/3’BamHI (relevant sites underlined) 
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Tags: hGH – TEV – MCS – TEV – SBP - stop 


















































1.2 Glycerol Stocks of DNA 
 
Location: Raines Glycerol Stock Box 
All stocks made with DH10B E.Coli cells unless otherwise noted in relevant purification 





- - - -  - IL2 - 
- NRGβ56 NRG1β hEGF  -  - IL2 - 






















- - - pSG 
HCSV0 
+ H2K 




- - - pSGHP1 
+ H2K 
- - - - 

















1.3 Purified Protein Stocks 
 
Assorted ErbB Family Ligands – Raines Box 2 
   
 Name   Concentration (year-mo-day) Volume aliquots (uL)/color 
 His- NRG1β  0.28 mg/mL (130307)  1mL/red pen clear 1mL tube 
 NRG1β  ~1mg/mL (130307)  1mL/black, clear 1mL tube 
 NRGβ56  9.48mg/mL (141113)  100µL/in blue cap 50mL tube 
 hEGF   1.7 mg/mL (150612)  120µL/in red cap 50mL tube  
 Herceptin Fab  0.35mg/mL (130911)  1mL/clear 1mL tube 
 Cetuximab Fab 3.7mg/mL (140627)  100µL/blue PCR tube, “C” 
 
Membrane Scaffold Proteins/Chapter 1 Related – Raines Box 3 
 
 Name   Concentration   Volume aliquots (uL)/color  
 His- MSP1D1  1mg/mL   25µL/purple PCR tube 
 MSP1D1  1mg/mL   25µL/yellow PCR tube 
 His-MSP1E3D1 1mg/mL   250µL/orange PCR tube 
 MSP1E3D1  1mg/mL   250µL/blue PCR tube 
 WT tEGFR  100uM    ~5uL/clear PCR tube 




1.4 Cell Lines – Raines Liquid Nitrogen Stocks 
Tower 11, Box 1 
*** Note: I clone stable cells lines may all be currently contaminated with IGF1R WT, 
confirmed in 1I-2, 5I-2, and 6I-1.*** 
 
Key to I clones (continuation of McCabe Thesis, see for more detail) 
6I: IGF1R (ECD) – cys – IGF1R (TM-ICD) | TM-ICD ~ 58.6kDa (895 – 1428) 
5I: IGF1R (ECD) – cys – IR (TM-ICD) | TM-ICD ~46.8kDa (957 – 1382) 
1I: IGF1R (ECD) – cys – EGFR (TM-ICD) | TM-ICD ~59.7kDa (643 – 1186 
  













- - - - - 
10 11 12 13 14 15 16 17 18 
- - - - - - - - - 
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46 47 48 49 50 51 52 53 54 
- - - - - - - - - 
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2.1.1 Leahy Lab Standard Purification Protocol – Neuregulin 
 
Developed by Leahy Lab, typed by Lily Raines 
Approximate Time to Completion: 5-6 days 
 
Trx-His-Tev-Nrg ~ 17kDa 
Cut Nrg ~ 6kDa 
 
1. Transform Trx-His-Tev-NRG1β plasmid into Origami E. coli strain – positive clones 
will be resistant to ampicillin 
- - - 
2. Morning: pick colony, grow 2.5mL seed culture during the day 
3. Use 0.2mL of culture to inoculate 100mL TB (terrific broth) + Amp, grow O/N 
shaking at 37oC. 
- - - 
4. Add 20mL culture to 1L of TB + Amp (in 2L flask), grow at 30 oC until OD600 = 1.5  
 Note: this will take 2 – 4 hours 
4. When OD600 = 1.5, induce expression of EGF with 1mM IPTG (from 0.5M IPTG 
stock, or 240mg/1mL per L growth). Let grow O/N at 25 oC.  
5. Harvest cells by centrifugation at 5,000g x 10min – freeze at -80 oC or lyse right away.  
 Note: take aliquot of induced cells to check for expression 
- - - 
6. Resuspend cell pellet in 20mL resuspension buffer. 
 Resuspension buffer: 50mM Na/KPO4 (pH 8.0), 500mM NaCl, 10mM imidazole  
7. Lyse cells in French pressure cell, add 2uL of benzonase/DNAse 1 before lysis 
 Note: Max volume French press: 30mL.  
8. Centrifuge at 14,000 rpm x 45 min at 4oC 
- - - 
9. Equilibrate 2mL nickel resin with resuspension buffer 
10. Apply cell lysate to equilibrated resin, batch bind with constant inversion at 4oC for 1 
hour. 
11. Wash column with 5CV (10mL) of resuspension buffer 
12. Elute protein with 3 – 4CV (6 – 8mL) elution buffer, collecting 1CV (2mL) fractions, 
using: 
 50mM Na/KPO4 (pH 8.0), 500mM NaCl, 50mM imidazole 
13. Elute remaining protein with 3 – 4CV (6 – 8mL) elution buffer, collecting 1CV 
fractions, using: 
 50mM Na/KPO4 (pH 8.0), 500mM NaCl, 250mM imidazole 
14. Confirm elution of NRG2β via Coomassie gel.  
15. Pool fractions containing NRG2β, add EDTA to 0.5mM and TEV (50-500ug, 
depending on patience/stocks) and dialyze O/N at RT vs. 4L 20mM acetate pH 5.0. 
- - - 
16. There will probably be a lot of precipitate (mostly cut thioredoxin) in the dialysis bag, 
but most of the NRG2β should still be soluble. Spin at high speed to remove precipitate 
 Note: Work quickly! The precipitate will come back with time and the sample may 
 need to be spun down again. 
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17. Assess if proteolysis is complete by SDS-PAGE. 
18. Once complete, run sample over 6mL Resource S column. Elute over 15-20CV. 
 Low salt buffer: 20mM acetate, pH 5.0 




2.1.2 Leahy Lab Standard Purification Protocol – EGF 
 
Developed by Kwangsoo Kim, typed by Lily Raines 
Approximate Time to Completion: >1 week 
Approximate Yield: 7mg EGF/2L cells 
 
1. Transform pT7HT-EGF into BL21(DE3) E. coli strain – positive clones will be 
resistant to kanamycin  
 Note: transformation efficiency may be low, easier to work from a glycerol stock 
2. Let 5mL seed cultures grow O/N (grow 10mL seed cultures/1L cells final volume) 
3. Add seed cultures to TB (terrific broth) + Kan, shaking at 37oC (1L media/4L flask), 
and grow until OD600 = 1 (this will take >3hours) 
4. When OD600 = 1, induce expression of EGF with 0.5mM IPTG (from 0.5M IPTG 
stock). Let grow for least 3 hours – O/N, then harvest cells by centrifugation at 5,000g x 
10min. 
- - - 
5. Resuspend cell pellet (use 2x final volume pellet, ~ 30mL/2L cells) and stir at RT for 1 
hour 
 Resuspension buffer: 0.1M Tris pH8.0, 6M Guanidine-HCl 
 Note: expect ~10g cell pellet/1L TB in 4L flasks  
6. Lyse cells using sonicator – power setting 5, 20 mins total lysis time, 5 sec on/5sec off 
7. Centrifuge at 15,000 – 20,000 rpm x 30 min at 4oC 
- - - 
8. Equilibrate 15mL nickel resin with: 
 0.1M sodium phosphate pH 6.0, 20mM imidazole, 0.5M NaCl, 8M Urea, 10% 
 glycerol. 
9. Apply spun cell lysate directly to nickel resin (do not batch bind/mix with resin) 
10. Wash column with 3CV (45mL) of equilibration buffer 
11. Elute protein with 5CV (75mL) elution buffer, collecting 1CV (15mL) fractions, 
using: 
 0.1 M Tris (pH 8.0), 0.5 M NaCl, 0.25 M Imidazole, 8 M Urea 
12. Confirm elution of EGF via Coomassie gel. Most protein will elute in 1st and 2nd 
fractions. 
13. Pool fractions containing EGF and concentrate to 10mL using 3kDa spin concentrator 
- - - 
14. To reduce EGF, add 5mM DTT (from 500mM DTT stock) to sample and incubate at 
37oC for 30min-1hour (without mixing) 
15. To refold protein, add EGF sample dropwise to refolding buffer to 10x volume 
(10mL sample to 90mL buffer) at RT 
 Refolding buffer: 0.1 M Tris pH 8.3, 0.5 M NaCl 
 Note: This can be done easily by adding the EGF sample to a gravity column and 
 letting it drain, drop by drop, into the refolding buffer. 
16. Dialyze the EGF O/N at 4°C in a buffer of 20 mM Tris (pH 8.0), 0.5 M NaCl, and 5% 
Glycerol 
 Note: some protein will precipitate. After dialysis is complete, centrifuge sample 
 at max speed to remove precipitate before proceeding to step 17. 
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- - - 
17. Run a second nickel column, using 5mL pre-packed column on AKTA (as another 
concentration step). Wash with 5CV equilibration buffer, elute with 10CV elution buffer, 
collect 5mL fractions. 
 Note: these buffers ARE NOT the same as the first nickel column 
 Ni-2 Equilibration buffer: 20 mM Tris (pH 8.0), 0.5 M NaCl, 5% Glycerol 
 Ni-2 Elution buffer: 20 mM Tris (pH 8.5), 20 mM NaCl, 0.25 M Imidazole, 5%  
  Glycerol 
18. Determine which fractions contain EGF via Coomassie gel. Pool fractions containing 
EGF 
19. Remove affinity tag by TEV proteolysis O/N at RT. 
 Use ~ protein:TEV (w/w) 50:1, or about 1mL Leahy Lab His-TEV 
- - - 
20. Monitor cleavage by Coomassie. Continue until >50% of protein is cleaved. 
21. Dialyze sample O/N at 4oC against: 20 mM Tris (pH 8.0), 0.5 M NaCl, 5% Glycerol 
- - - 
22. To remove His-TEV and to isolate cleaved EGF, run another nickel column. Use a 
pre-packed column and equilibrate with Ni-2 equilibration buffer [20 mM Tris (pH 8.0), 
0.5 M NaCl, 5% Glycerol]. Load sample via syringe and collect flow-through 
23. Concentrate flow-through to 5mL using spin filters, pore size 3kDa 
- - - 
24. Run concentrated sample over Superdex 75 16/60 column, equilibrated in: 
 20 mM Hepes, pH 7.4, 1 mM EDTA, 150 mM NaCl 
25. Store at 4oC as 40% glycerol solution (6mL EGF + 4mL glycerol), or at -80oC long 
term 




2.1.3 Leahy Lab Standard Purification Protocol – TEV/PreScission 
 
Approximate Time to Completion: 2 days 
Approximate Yield: >10mg 
 
Notes:  
1. Both proteins are not very stable in low salt. Prescission is more active in high salt. 
2. Expression at 25 ºC is critical. Higher temperatures give insoluble protein and lower 
temperatures give less protein. 
3. Ensure that protein isn’t lost during the Ni2+ wash steps. 
4. Prescission and can undergo at least 4 cycles of freeze-thaw without losing activity. 
 
Purification 
1. Grow the BL21(DE3)CodonPlus-RIL strain with the TEV-S219V plasmid or the 
Rosetta2 strain with pBrian-Prescsission plasmid in 2 L TB+Amp+Chloramphenicol at 
37 ºC until OD600 ~1.5.   
2. Induce with 1 mM IPTG and let the induction last overnight at 25 ºC.  
- - - 
3. Pellet the cells, then resuspend in  
 35 mM PO43- pH 8.0, 400 mM NaCl, 20 mM imidazole, 5 mM β-
mercaptoethanol,  
 1uLDNase and 1uL Benzonase/10mL lysate.  
4. Lyse via French Press. 
5. Centrifuge at 20,000 x g for 50 min at 4 ºC. Filter the supernatant through 0.45 µm 
filter 
6. Incubate the lysate with 12-15 ml Ni2+-NTA resin for 15 min at 4 ºC. 
6. Pour the suspension into an empty column and drain. 
7. Wash out unbound protein with 2 CVs of Ni2+ Bind Buffer. 
8. Wash the column with 4 CVs  
 20 mM PO43- pH 8.0, 40 mM NaCl, 25 mM imidazole, 10% glycerol. 
9. Elute the column with 3 CVs of 
 10 mM PO43- pH 7.0, 40 mM NaCl, 250 mM imidazole, 10% glycerol. 
10a. For TEV: pool fractions and add 100% glycerol to 50% v/v final concentration at ~1 
mg/ml TEV    and freeze in 1 ml aliquots at -80 ºC. 
10b. For Prescission: pool fractions and either freeze directly or dilute to 1 mg/ml with 20 
mM PO43-    pH 8.0, 400 mM NaCl, 10% glycerol and freeze at -80 ºC. 
- - - 
 
OPTIONAL: S-column after Ni-NTA, better to skip this step!!! 95% pure after Ni-NTA 
and will take hit in final yield. If desired, run as below 
10. Dilute the elution 2 fold with 10 mM PO43- pH 7.0, 10% glycerol and load onto 6 ml 
Resource S column. 
 Buffer A= 20 mM PO43- pH 7.0, 20 mM NaCl, 10% glycerol. 
 Buffer B= 20 mM PO43- pH 7.0, 1 M NaCl, 10% glycerol  




2.1.4 Leahy Lab Standard Purification Protocol – EndoF 
 
Developed by Samuel Bouyain 
Approximate Time to Completion: 3-4 days 
Approximate Yield: 50 - 100mg 
 
Notes: 
1. Endoglycosidase F1 has been cloned into pT7 with His6 and TEV site. Two versions 
of the protein have been made: one wild type and one with CysSer mutation (there is only 
one cysteine in the mature protein). The wild type and mutant endoglycosidase F1 have 
been named EndoF1 and,EndoF6, respectively. The following protocol was used to 
produce both enzymes and the protein will be referred to as EndoF throughout. 
2. The tag could be removed by TEV but is left on so that it can be removed by Ni 
affinity chromatography after the deglycosylation reaction is over. The protein is not pure 
but could in theory be purified by ion exchange on Resource S at pH 7.0 (pl of 9.0). 
However, it seems unstable at low salt and will partly crash out in dialysis bag in 20 mM 
NaPi 7.0. Adding salt to 500 mM solves this problem. 
3. EndoF cloned from Flavobacterium meningosepticum 
4. Absorbance for 1 mg/ml His-TEV-EndoF: 0.856 
 
Purification 
1. Transform 1 ul of EndoF plasmid into BL21(DE3) cells. Add 50 ul of 50% glucose on 
the agar when plating the cells. 
- - - 
2. Take a swab of colonies on the plate and add to a 100 ml flask of LB-Kan (in a 500 ml 
flask), grow at. 37°C for 2 to 3 hours, shaking 225 rpm. 
3. Inoculate 100 ml of culture to a 1000 ml flask of TB-Kan (in a 2Lflask), grow at 37°C 
until OD550 is about 2.0 (more is probably fine).  
 This takes about 2 to 4 hours. Leaving the flasks in the incubator, decrease 
 temperature to 30°C and grow for a further 1 hour. 
4. Add IPTG freshly dissolved in water to a final concentration of 1 mM (e.g. dissolve 
240 mg in 1 ml of water and add the whole solution to a 1000 ml culture). Grow 
overnight (16 to 20 hours). 
- - - 
5. Spin cells down. At this stage, they can be frozen at -80°C or lysed straightaway. Take 
an aliquot of induced cells to check for expression on a polyacrylamide gel. 
6. Resuspend cells in 20 ml of  
 500 mM NaCl, 10 mM imidazole, 20 mM Na/K P04 pH 8.0 (this is the loading 
buffer).  
7. Add 200 units benzonase.  
8. Lyse in French press with two passes. 
9. Spin down lysate. 14,000 rpm for 45 minutes in SA-600 works.  
10. Filter supernatant with 0.45 µm steriflip. 
11. Add supernatant to 5 ml-column of chelating sepharose fast flow (Amersham) loaded 
 with nickel sulfate 
12. Wash with 5 CV of loading buffer.  
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13. Perform three elutions:  
 3 CV of loading buffer with 50 mM imidazole,  
 3 CV loading buffer with 100 mM imidazole  
 3 CV loading buffer with 250 mM imidazole.  
14. At this stage, run a gel. Pool 100 mM and 250 mM imidazole fractions. 
15. Concentrate protein to less than 10 ml, some cloudiness may appear.  
16. Filter protein using 0.45 µm filter and load onto Superdex 75 26/60 in 
 20 mM NaPi 7.0, 500 mM NaCl.  
17. Pool pure fractions (elution volume between 160 and 180 ml.) 




2.1.5 Leahy Lab Standard Purification Protocol – EndoH 
 
Developed by Samuel Bouyain 
Approximate Time to Completion: 2-3 days 
Approximate Yield: 57mg/2L 
 
Notes: 
1. Endoglycosidase H has been cloned into pPROHEX HT (Amp resistance). The 
plasmid must transformed into Rosetta2 cells (Novagen) for efficient expression. These 
cells must be grown in the presence of chloramphenicol. 
2. EndoH is cloned from Streptomyces picatus 
3. MW Endo H is 29,000 Da 
 
Purification 
1. Transform 1 µI of EndoH plasmid into Rosetta2(DE3) cells (Novagen). 
- - - 
2. Prepare 4 culture tubes with 5 ml of LB with Amp and Chi (100 µg/ml and 34 µg/ml, 
respectively), inoculate each tube with a colony from the plate.  Alternatively, one can 
start from frozen stock.   
3. Grow at 37°C overnight, shaking 225 rpm. 
- - - 
4. Inoculate 1O ml of culture to a 1000 ml flask of TB-Amp/Chi (in a 2 I flask), grow at 
37°C until OD600  is about 2.0.   
5. Leaving the flasks in the incubator, decrease temperature to 25°C and grow for a 
further 1 hour. 
6. Add IPTG freshly dissolved in water to a final concentration of 1 mM (e.g. dissolve 
240 mg in 1 ml of water and add the whole solution to a 1000 ml culture).  
7. Grow overnight (16 to 20 hours). 
- - - 
8. Spin cells down. At this stage, they can be frozen at -80°C or lysed straightaway. Take 
an aliquot of induced cells to check for expression on a polyacrylamide gel. 
9. Resuspend cells in  
 50 ml of 500 mM NaCl, 50 mM Na/K P04 pH 8.0 (this is the loading buffer).  
10. Lyse in microfluidizer, rinse cell with 50 ml of loading buffer. 
11. Spin down lysate. 16,000 rpm for 30 minutes in SS-34 works.  
12. Filter supernatant with 0.45 µm steriflip. 
13. Add supernatant to 8 ml-column of 1:1 slurry of His-select resin (Sigma) in loading 
buffer. Batch-bind for 1h on rotisserie. 
14. Load lysate and resin onto column.   
15. Wash with 5 CV of loading buffer with 20 mM imidazole.  
16. Elute with 2.5 CV of:  
 10 mM Tris pH 8.0, 40 mM NaCl, 10% glycerol and 200 mM imidazole. 
 Keep an aliquot of the eluate for the gel. 
17. Add eluate slowly to 40 ml of 20 mM Tris pH 8.0, 10% glycerol while stirring.  Filter 
 through 0.45 µm filter. 
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18. Load onto HiPrep Q XL column on akta equilibrated in 20 mM Tris pH 8.0, 10% 
glycerol.  
19. Wash column with 3 CV of low salt buffer.   
20. Elute with salt gradient to 500 mM over 12 CV. 
21. Pool fractions.   
 Check for aggregation by running an aliquot onto analytical gel filtration column.  
 The last time the protein was produced, yield was 57 mg for 2 liters of culture 
 with all the protein being monomeric (Mw - 29,000 Da). 







2.1.6 Leahy Lab Standard Purification Protocol – PNGaseF 
 
Developed by Samuel Bouyain 
Approximate Time to Completion: 2-3 days 
Approximate Yield: 4mg/2L 
 
Notes: 
1. PNGaseF = peptide-N glycosidase F 
2. PNGaseF has been cloned into pMal-p2x (maltose-binding protein with periplasmic 
expression, Amp resistance). 
3. MBP-PNGaseF: 701 amino acids, M=77183.41 Da, isoelectric point 5.49,  




1. Transform 1 µI of PNGaseF plasmid into BL21(DE3) cells (Novagen). 
- - - 
2. Prepare 4 culture tubes with 5 ml of LB with Amp (100 µg/ml), inoculate each tube 
with a colony from the plate. Alternatively, one can start from frozen stock.  Grow at 
37°C overnight, shaking 225 rpm. 
- - - 
3. Inoculate 10 ml of culture to a 1000 ml flask of TB-Amp (in a 2L flask) containing 2 g 
of glucose/L 
4. Grow at 30°C until OD600 is about 1.5.   
5. Leaving the flasks in the incubator, decrease temperature to 23°C and grow for 1 hour. 
6. Add IPTG freshly dissolved in water to a final concentration of 1 mM (e.g. dissolve 
240 mg in 1 ml of water and add the whole solution to a 1000 ml culture). Grow 
overnight (16 to 20 hours). 
- - - 
7. Spin cells down. At this stage, they can be frozen at -80°C or lysed straightaway. Take 
an aliquot of induced cells to check for expression on a polyacrylamide gel. 
8. Resuspend cells in  
 50 ml of 250 mM NaCl, 25 mM NaP04  pH 8.0 and 0.5 mM EDTA (this is the 
loading buffer). 
9. Lyse in microfluidizer, rinse cell with 50 ml of loading buffer. 
10. Spin down lysate. 16,000 rpm for 30 minutes in SS-34 works.  
11. Filter supernatant with 0.45 µm steriflip. 
12. Add supernatant to 20 ml of amylase resin (New England Biolabs) as a 1:1 slurry in 
loading buffer (so 10 ml bed volume).  Batch-bind for 1h. 
13.  Load lysate and resin onto column.   
14. Wash with 10 CV of loading buffer.   
15. Elute with 3 CV of loading buffer with 10mM maltose. 
16. Desalt or dialyze eluate into 20 mM Tris pH 8.0.   
17. Filter through 0.45 µm filter. 
18. Load onto HiPrep Q XL or Resource Q column on akta equilibrated in 20 mM Tris 
pH 8.0.  
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19. Wash column with 3 CV of low salt buffer.   
20. Elute with salt gradient to 1000 mM over 15 CV. 
21. Pool fractions.  
 Check for aggregation by running an aliquot onto analytical gel filtration column. 
 The last time the protein was produced, yield was 4 mg for 2 liters of culture. The 
 enzyme was active.  One might be able to increase the yield by raising the 
 temperature of the induction maybe to 25°C or 30°C, but there is a chance that 
 this would overload the secretion system of E. coli, resulting in no active protein 




2.1.7 Leahy Lab Standard Purification Protocol – tEGFR 
 
Developed by Kwangsoo Kim, typed by Lily Raines 
Approximate Time to Completion: 4 days 
Approximate Yield: 100 – 200ug tEGFR/1L of cells 
 
Note: store buffers at 4oC and top off DTT over time 
 
Materials Required 
1g 528-coupled CnBr beads per liter of cell homogenate 
1.5mg (at least!) His-tag removed EGF 
Multiple 0.45µM steriflips or larger vessel vacuum filters (for clarifying cell 
homogenate) 
30uL total, 10uL Halt protease inhibitor cocktail/1mL lysate 
tEGFR lysis buffer: 40mM Hepes 7.4, 1% TX-100, 20% glycerol 
 1L – 40mL 1M Hepes, 10mL TX-100, 200mL glycerol 
Add Halt protease inhibitor cocktail (Pierce, 100 ul in each tube), 10 ul per 1mL lysate, 
before lysis. 
Receptor buffer: 20mM Hepes 7.4, 150mM NaCl, 1mM EDTA, 0.5mM DTT,  
 0.03%  DDM, 10% glycerol 
  1L – 20mL 1M Hepes stock, 30mL 5M NaCl stock, 2mL 0.5M EDTA,  
  1mL 500mM DTT, 0.3g DDM, 100mL glycerol 
Wash solutions:  
 50mL receptor buffer + 1M NaCl = 10mL 5M NaCl stock to receptor buffer. 
 25mL receptor buffer + 1M Urea = 1.5g urea to receptor buffer. 
tEGFR Superose 6 buffer: 20mM Hepes 7.4, 150mM NaCl, 1mM EDTA, 0.5mM DTT, 
 0.03% DDM, 5% glycerol, 1mM PMSF 
  1L – 20mL 1M Hepes stock, 30mL 5M NaCl stock, 2mL 0.5M EDTA,  
  1mL 500mM DTT, 0.3g DDM, 50mL glycerol, 10mL 100mM PMSF  
  (made in isopropanol) 
 
Purification 
1. Thaw the cell pellets, add an approximately equal amount of lysis buffer to pellets (but 
at least 30mL!) 
2. Lyse cells using a sonicator for 3 x 20s bursts at setting 3 (30-50% output) with 1 min 
off between sonications. Lyse with sample on ice in cold room. 
3. Centrifuge cell homogenate at 14,000 x rcf for 30 min at 4°C 
 Note: Can leave lysate to rotate in the cold room for 1 hour for more extraction 
time? 
4. Filter supernatant using vacuum driven filters (steriflips or large ones) with 0.45µM 
cut-off. (0.22µM will work but will take longer).  
 Note: Approximate time: 45 minutes – 1 hour with large volume (500mL) filters. 
5. Apply filtered supernatant to 528-coupled beads, inverting overnight at 4°C. 
- - - 
6. Transfer beads to a vacant gravity/econocolumn. 
7. Wash the beads as follows: 
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 - 25mL receptor buffer 
 - 25mL receptor buffer + 1M NaCl 
 - 25mL receptor buffer 
 - 25mL receptor buffer + 1M NaCl 
 - 25mL receptor buffer 
 - 25mL receptor buffer + 1M Urea 
 - 50mL receptor buffer 
Approximate total time (FT to first elution) = 3 hours 
8. Transfer beads to a 15mL Falcon tube, spin down at 1,200 x rcf for 5 minutes at 4oC, 
and remove leftover wash solution. 
9. To elute tEGFR, add an equal volume of receptor buffer with EGF at 50µg/mL, then 
incubate with inversion at room temperature for 30 minutes. 
 For 1L beads, expect to add 2 – 3.5mL at 50µg/mL for 100µg EGF per elution.  
10. After 30 minutes, spin solution at 1,200 x rcf for 5 minutes at 4oC and collect first 
‘elution fraction. 
11. Repeat for a total of twelve elutions. Approximate time: 7 hours 
 Expect ~50% capture on 528 beads 
12. Run an SDS-PAGE gel to determine which elutions contain tEGFR 
13. Pool all tEGFR containing solutions. 
14. To deglycosylate, add 10µL of EndoH and EndoF per 10mL protein and let incubate 
overnight with inversion at 4oC. Minimum incubation time is 2 – 3 hours. 
- - - 
15. Concentrate deglycosylated tEGFR to 240µL to load onto Superose 6 analytical gel 
filtration column. 
16. Run Superose 6 column at 0.7mL/min and collect 0.5mL fractions. Determine which 
fractions contain tEGFR by SDS-PAGE. 





















2.2.1 Leahy Lab Technique Protocol – ELISA Plate Preparation 
 
Developed by Patti Longo and Min-Sung Kim, typed by Lily Raines 
Approximate Time to Completion: 3 hours 
Makes 30 plates 
 
Materials Required 
Corning #9018 EIA/RIA 96-well Flat bottom plates 
Corning Plate Sealers, #3095 
~5mL Dialyzed calf serum (DCS) of fetal calf serum (FCS) 
2.25mg HGH-B monoclonal antibody (protein A purified from mouse ascites) 
2L Phosphate buffered saline 0.1% Tween-20 (PBST) – use from carboy near Lily’s 
bench 
1L 50mM Sodium Carbonate Buffer, pH 10.4 
 - 4.24g Na2CO3 + 0.84g NaHCO3 per 1L H2O. Set pH to 10.4 
300mL mAb solution for coating plates (need ~10mL mAb solution per plate) 
 - 7.5ug/mL HGH-B mAb in 50mM sodium carbonate buffer 
300mL plate blocking solution (need ~10mL blocking solution per plate) 
 - 1% DCS or FBS added to 50mM sodium carbonate buffer; 3mL in 300mL total 
volume 
 
Preparing ELISA plates 
1. Coat plates by adding 100uL of mAb solution to each well of a 96-well plate  
 - apply with multichannel pipette from plastic trough for fast application. Work 
 quickly! 
2. Seal and leave plates at 37oC for 1 hour 
 - stack plates for easier transport, use removable plastic plate seal for topmost 
 plate during all incubations to prevent plates from drying out. 
3. Flick coating solution out of plates into sink and blot each plate one time with paper 
towel. 
 DO NOT wash with PBST 
4. Add 100uL DCS/FCS blocking solution to each well 
5. Cover and leave plates at 37oC for 1 hour 




- To prevent plates from drying out over long-term storage, keep plates in sealed boxes 
with a moist paper towel inside and a plate seal on the topmost plate.  






2.2.2 Leahy Lab Technique Protocol – ELISA 
 
Developed by Patti Longo and Min-Sung Kim, typed by Lily Raines 
Approximate Time to Completion: 3 hours 
Expected volumes listed per ELISA plate. 
 
Notes:  
- For a sample with ~0.1mg/L expected hGH concentration, dilute by 10 fold to stay 
within hGH standards. If approximate levels unknown, try 1x, 10x, and 100x dilutions. 
- All samples are done in duplicate. 
- Antibody solutions and HBSS/1%FCS can be made ahead of time and are stored in 
Jackie’s refrigerator at 4oC 
- Dispense antibody, TMB, and sulfuric acid solutions from plastic troughs using 
multichannel pipettes for easy and quick sample application. 
 
Materials Required 
Corning #9018 EIA/RIA 96-well Flat bottom plates 
Corning Plate Sealers, #3095 
25mL HBSS/1%FCS or 1%DCS 
 - HBSS = Hanks balanced salt solution, FCS/DCS = dialyzed or fetal calf serum 
30uL Leahy lab human growth hormone stock for standards 
 - Leahy lab hGH stock is 640ng/mL with aliquots stored at -80oC, can store at - 
 20oC 
10mL of 1:10,000 α-hGH polyclonal antibody diluted in PBST 
 - α-hGH pAb From Research Diagnostics (#RDI-HGHabrX1) 
10mL of 1:10,000 Goat α-rabbit IgG conjugated horse radish peroxidase (GAR-HRP)  
 - GAR-HRP From Santa Cruz biotech, #SC-2301) 
10mL 3,3’,5,5’ tetramethyl benzidine (TMB, Sigma #T-8665) 
 - put at RT after adding samples to plates. 
5mL 1M Sulfuric acid 




1. Serially dilute hGH standards in HBSS/1%FCS for 200uL of standards at 32, 16, 8, 4, 
2, 1, 0.5, and 0ng/mL 
 - If using Leahy lab stock at 640ng/mL, first dilute 10-fold into 300uL for 
 64ng/mL, Then add to 300uL of HBSS/1%FCS for the 32ng/mL sample. Mix 
 thoroughly, then repeat until  have 300uL of all hGH standards, taking 250uL of 
 diluent for 0ng/mL sample. 
2. Add 100uL (or desired volume) of hGH-containing samples diluted in HBSS/1%FCS 
to wells in a pre-coated 96-well plate. 
3. Incubate, covered with a plate seal, at 37oC for 45 minutes. Then put TMB at RT 





5. Add 100uL of 1:10,000 dilution of polyclonal α-hGH to each well. 
6. Seal and leave plates at 37oC for 30 minutes 
7. Wash plate 5 times with PBST. Flick out excess wash buffer. 
8. Add 100uL of 1:10,000 dilution of GAR-HRP to each well. 
9. Seal and leave plates at 37oC for 30 minutes 
10. Wash plate 5 times with PBST. Flick out excess wash buffer. 
11. Add 100uL of TMB to each well and wait for standards to develop a blue color, ~3-5 
 minutes.  
 - Want to see a hint of blue in 0.5 - 1ng/mL samples and none in 0ng/mL sample. 
12. Stop reaction by adding 50uL of 1M sulfuric acid to each well. 
13. Read plate at 450/655nm, with 5 seconds of mixing before detection. 
14. Fit standards with a logistic fit, read-out from Leahy lab set-up will be in ug/L 




2.2.3 Leahy Lab Technique Protocol – Western Blot 
 
Semi-Traditional Western 
Total time: ~4 hours 
Traditional Western 
Total time: 2 days 
 
1. Run acrylamide gel with desired protein samples, using Western compatible 
ladders 
  MagicMark XP Western Standard, prestained: SeeBlue… 
2. Transfer using iBlot system or traditionally 
 iBlot: follow instructions by instrument 
 Traditional: combine 50mL 10x transfer buffer, 125mL methanol, 325mL ddH2O. 
  Run at 35V 120mA for 1.5 hours. 
3. Block in 15-20mL of 5% BSA or 5% powdered milk in ELISA wash buffer 
 at least 1 hour, up to overnight 
4. Add primary antibody directly to BSA/milk solution, incubate with shaking for 
 30mins 
 See “Leahy Lab Western Antibody Dilutions” document 
5. Wash with ELISA wash buffer 5 minutes, discard buffer, then repeat for a total of 
 3x 5 minute washes (15 minutes total) 
6. Add secondary antibody to 15-20 mL of 5%BSA or powdered milk, incubate blot 
 for 30 mins 
7. Wash as in Step 5 
8. Dry blot between paper towels/chemwipes. Incubate in developing solution for 5 
 minutes 
9. Analyze by film or Typhoon phosphorimager 
 
Notes: 
ELISA Wash buffer: PBS + 0.1% Tween 20. 
Traditional 10x Transfer buffer:  
 14.5g Tris base, 72g glycine, ddH2O to 1L. 
 
Developing with ECL-Plus and imaging on the Typhoon (filter 520BP40 laser457nm) 





2.2.4 Leahy Lab Technique Protocol – Standard Western Dilutions 
Key 
GAR: goat a. rabbit 
GAM: goat a. mouse 
(T): traditional western  
(S): SnapID 
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2.2.5 Leahy Lab Technique Protocol – CNBr Bead Coupling 
 
Developed by Kwangsoo Kim, adjusted by Zhihong Wang, typed by Lily Raines 
Approximate Time to Completion: 4 hours, overnight incubation. 
Approximate Amount of Beads/prep: 0.5g 528-coupled resin/1L HEK 293’s 
All steps written for coupling 1g of beads 
 
Materials Required: 
STORE ALL SOLUTIONS AT 4oC BEFORE USE 
 1g CNBr-activated beads (GE healthcare), volume ~ 3.5mL/1g 
 528 EGFR antibody (stored in 0.1M NaHCO3 pH 8.0, 0.5M NaCl, at 5 –   
 10mg/mL)  
  –  10mg antibody/1g beads 
 1 mM HCl - ~150mL/1g bead coupling 
 Coupling buffer: 0.1 M NaHCO3 pH8.3, 0.5 M NaCl - ~150mL/1g beads 
 Quenching buffer: 0.1 M Tris pH 8.0 – ~50mL/1g beads  
  (1M ethanolamine pH 8.0 also works) 
 Storage buffer (20 mM Hepes pH 7.4, 150 mM NaCl - ~100mL/1g beads 
 Receptor buffer: 20 mM Hepes pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 10%  
  Glycerol, 0.5 mM DTT, 0.03% DDM – for tEGFR purification later. At  
  LEAST 1L/prep 
 
1. Weigh out desired amount of sepharose beads 
2. Add 10 resin volumes of cold 1mM HCl 
3. Incubate with constant inversion (i.e. on a tube rotator) for 30min at 4oC 
4. Divide the resin between two 15mL falcon tubes (~0.5g beads each), then add 10mL of 
1mM HCl, invert a few times, then centrifuge at 1,200 x g for 3min at 4oC 
5. Repeat for a total of three washes. 
6. Add 10mL of coupling buffer to each tube and wash similarly as in steps 4 and 5 for a 
total of three washes. 
7. Re-check the volume of beads, then add an equal volume of coupling buffer 
8. Add the 528 antibody solution to each tube (adding 5mg/0.5g beads) and incubate at 
room temperature with constant inversion for 2 – 4 hours.  
9. Note final antibody concentration of the above reaction. 
10. After 2 – 4 hours, wash the resin with 10mL of coupling buffer, then spin at 1,200xg 
for 3min at 4oC and retain the supernatant. Check the A280 of the wash supernatant. 
 If A280 < 0.1, proceed with wash and storage steps. Otherwise continue coupling. 
11. Wash as in step 6 with 10mL of coupling buffer for a total of three washes 
12. Block unbound active sites on beads by washing with at least 3 resin volumes of 
quenching buffer for a total of three washes. 
13. Let beads invert overnight (or sit at room temperature for 2 hours) at 4oC. 
14. The next day, wash the coupled resin as in step 6 with 10mL of storage or receptor 





2.2.6 Leahy Lab Technique Protocol – Antibody Digestion 
 
Developed by Zhihong Wang, notes from Lily Raines 
Protocol written specifically for digestion of cetuximab, should be broadly applicable. 
 
Solutions: 
 200mM L-Cysteine in 75mM PO4
3- , pH7.0, 75mM NaCl 
500mM Iodoacetamide in 75mM PO4
3- , pH7.0, 75mM NaCl 
Papain stock: 25mg/ml 
 
Protocol: 
1. Digest 2mL Cetuximab (7.7mg/ml) with 1% papain (6uLof papain stock) in the 
 presence of 10mM Cysteine at 37°C for 3hr 
2. Stop the reaction by adding 50mM Iodoacetamide (200uL stock to 2mL reaction 
 buffer), incubate at 37°C for 15-30 min, then put the sample on ice.  Load 1uL 
 reaction buffer to non-reducing SDS-PAGE gel to check how the reaction goes. 
3. Dilute 2mL reaction buffer to 10 mL with 10mM NaCl, 20mM Tris pH8.0. Use 
 10mL superloop to load the proteins onto Mono QTM 5/50 GL column. Check the 
 fractions with Coomassie stain.  
  Fab will not bind to the Q column and will be in the FT!  
  Note: I loaded the sample three times to Mono Q column.  
4. Combine all the fractions and concentrate with Mw 10,000 cut-off concentrator to 
1 mL. 
  Note: if you load a 5mL HiTrap Q column (freshly cleaned) and flow at  
  1mL/min you can get all the Fc to bind in one go. 
5. To get more pure Fab, size-exclusion column can be used after Mono Q  
 Note: Zhihong and Lily skip this step, but recommended in some protocols/some 
 antibodies. 
6. Concentrate Fab to a final concentration of ~6mg/ml, add 40% glycerol, aliquot 
 (~100ul per aliquot), and keep them @-80.  
 
Notes:  
Since Fc and Fab have similar size, make sure you know capture the right protein. (Fc 





2.2.7 Leahy Lab Technique Protocol – BCA Assay 
 
Abbreviated notes from manual 
Approximate Time to Completion: 45 minutes 
 
“Microplate method” 
1. Prepare 0.2mL working reagent (WR) per sample (including standards) 
 1 part B to 50 parts A  
2. Prepare 8 standard dilutions, prepare 25uL 
standard standard ug/mL uL stock 
uL 
diluent Total volume 
A 2000 25 0 25 
B 1500 18.75 6.25 25 
C 1000 12.5 12.5 25 
D 750 12.5 B 12.5 25 
E 500 12.5 C 12.5 25 
F 250 12.5 E 12.5 25 
G 125 12.5 F 12.5 25 
H 25 5 G 20 25 
I 0 0 25 25 
 
3. Take 10 - 25uL each unknown and each standard into separate labeled tubes 
4. Add 200uL WR to each, keep at 37oC for 30mins 
5. Read A562 on nanodrop, blank instrument with water and subtract “blank” standard 
from all standards and unknowns. 
 





2.2.8 Leahy Lab Technique Protocol – Cell Surface Biotinylation 
 
Developed by Jackie McCabe, modified from EZ-Link Sulfo-NHS-SS-Biotin Protocol 
 
Materials 
Biotin Solution – 1.4mL/well of a 6-well plate; 10mL/T75 flask 
- Dilute 0.25mg EZ-link Sulfo-NHS-SS-biotin/mL of PBS 
PBS on ice – 4mL/well 
Quench solution: 50mM Tris pH 7.4 – 1mL/well 
Lysis buffer: RIPA + 1mM Na3VO4 – 25uL/well 
Streptactin Resin – 20uL/well 
 
Protocol 
1. Plate cells at 1x106/well, wait at least two hours or overnight to proceed 
2. Wash cells two times with ice-cold PBS 
3. Bring to cold room 
4. Add 1.4mL of biotin solution per well, leave at 4oC for 15 minutes 
5. While still in cold room, quench with 0.933mL of 50mM Tris pH 7.4 
6. Cells will become non-adherent, so suspend cells and spin at 1,000 x g for 15 minutes 
7. Wash with ice cold PBS, spin and repeat for a total of two ice cold PBS washes 
8. Add 25uL lysis buffer/sample 
9. Add each sample to 10 – 20uL of streptactin resin, mix for 2 hours at RT 
10. Spin, then wash resin with 1% NP-40, 1% SDS in PBS 
11. Spin, then wash resin with 0.1% NP-40, 0.5M NaCl in PBS 




- Dispose of streptactin resin after use 
- MW of Sulfo-NHS-SS-Biotin: 607g/mol 
- Source protocol recommends 80uL of 10mM Biotin (6mg/1mL) per milliliter of for 
25x106 cells/mL 
 > for 2.5x106cells/mL, use 0.6mg/1mL biotin; for 1x106 cells/mL use 0.25mg/mL 
biotin 
- Source protocol recommends 15mL biotin be quenched with 10mL quench solution 






2.2.9 Leahy Lab Technique Protocol – Immunoprecipitation 
 
Developed by Jennifer Kavran and Jackie McCabe 
Approximate time to completion: ~ 8 hours 
 
Materials 
RIPA supplemented with (250uL per well + extra for BCA dilutions): 
- 1uL benzonase/10mL RIPA 
- 1mM PMSF; 100uL of 100mM PMSF stock/10mL RIPA 
- 1mM Na3VO4;  14uL of 0.7M Na3VO4 stock/10mL RIPA 
- 10mM iodoacetamide (if using to prevent additional cysteine cross-linking);  
200uL of a 0.5M stock/10mL RIPA 
 Make 0.5M iodoacetamide stock solution right before use, not stable 
Dynabead wash solution: RIPA + 1mM Na3VO4 – 3mL/sample 
Ham’s F12 + 1mg/mL BSA – 8mL/well 
PBS – on ice, 2mL per well 
Anti-HA conjugated Protein G dynabeads – 20uL/sample 
- Add 200ng anti-HA to 0.6mg protein G dynabeads in PBS + 0.01% Tween 20 
- rotate 30 mins at RT, store at 4oC 
Dynabead magnets, etc. 
2X SDS loading buffer + fresh 10% BME – 30uL/sample 
- freshly added 10% β-mercaptoethanol: bottle <1yr old, kept at 4oC 
 
Protocol 
1. Plate cells at 1.0 x 106 cells/well, wait at least two hours to proceed 
2. Wash cells three times with 2mL of Ham’s F12 + 1mg/mL BSA 
3. Serum starve in Ham’s F12 + 1mg/mL BSA for 3 hours at 37oC 
4. Stimulate with appropriate ligand for 5 minutes at 37oC 
 IGF1 – 20nM | 200nM insulin | 100ng/mL EGF 
5. Wash cells with ice-cold PBS, 2mL/well 
6. Lyse cells with 250uL RIPA/well at 4oC for 30 minutes. 
7. Clarify lysates by spinning at maximum spin at 4oC for 15 minutes 
8. Determine protein concentration using BCA assay 
 – see separate protocol 
9. Normalize lysate volumes relative to most dilute sample, dilute others with RIPA + 
Na3VO4 to 200uL 
10. Add 200uL of normalized lysate to 20uL of HA-conjugated protein G dynabeads. 
11. Incubate O/N at 4oC OR 2 hours at RT 
 This depends on how sensitive your protein is to degradation. Try O/N first and 
then 2 hours if  yields are low 
12. The next day wash three times with 1mL RIPA + 1mM Na3VO4 
 For washes, let reactions stir for 5 minutes before pull-down  
 For dynabeads, allow 2 minutes for beads to bind to magnet to reduce sample loss 
 For protein G beads, spin at recommended speed and time (protein G manual) 





- For dynabeads, always dispose of beads after use 
- For protein G beads, spinning beads for 15 – 30 minutes at maximum speed after 
elution improves gels 
- Jennifer always kept samples at 4oC b/c IGF1R is super sensitive to proteolysis. 
- For Kavran et al, JMK froze samples at –20 overnight after elution (where stimulation, 
lysis, pull-down for 2 hours, and elution were all performed on the same day) and ran 




2.3.1 Leahy Lab Cloning Protocol – General Cloning Protocols 
 
PCR Reactions  
10uL Phusion HF buffer 
5uL DMSO, if needed 
2uL dNTP (10mM working stock) 
1uL each template 
2uL each primer (1:10 dilution of 100nM stock) 
0.5uL enzyme 
>ddH2O to 50uL 
 
PCR Tanneal – Tm lower + 5 
Agarose gels – 1g/100mL TAE buffer, ~6uL ethidium bromide 
 
Cutting Vectors (for pre-cut stocks) 
To 50µL, add 
 1uL each enzyme 
 6uL BSA, 100ug/mL (1x, NEB) 
 6uL NEB double digest compatible buffer 
Leave reaction for 4 hrs at 37oC for vectors, 1 hour for inserts 
Add 1 uL CIP (calf intestinal phosphatase) if using for vector stocks (to prevent re-
ligation) 
Leave for 30 mins at 37oC 
Elute on agarose gel, extract, get concentration, then ligate 
 
Ligations (insert into vector) 
Use ~[cut vector] to [cut insert], 20uL reaction mix 
 1uL vector 
 2uL bfr T4 ligase 
 0.5uL T4 ligase 
 __uL insert  
 ddH2O to 20uL 
Leave at 16oC O/N or at RT 1 hour 
Most transformations: half of ligation mixture (10uL) to 100uL DH10B 
 
Enzyme Digestions (confirm proper insert size) 
20ul/well 
 2uL compatible digest buffer 
 2uL BSA 
 15uL ddH2O 
 ~1uL template/well 
 Negligible enz (1uL each to overall mix) 
Make Bfr/BSA/H2O mixture for all wells, add 1uL each enzyme to master mix. 
Incubate at 37oC for 2 hours 





60bp> for IDT, try and end with one or two G/C at 3’ end, no more than two. ~20-30 bp 
fine sqn 
If adding restriction site, give 6-8 bp random DNA after 5’ end. A/T better, don’t change 
Tm much. 
 
5x LDS recipe     For 25mL 5x LDS 
 5% LDS (lithium dodecyl sulfate)  1.25g LDS 
 0.1% bromophenol blue   0.025g bromophenol blue 
 200mM Tris pH 6.8   5mL 1M Tris-HCL 
 1.25M sucrose    10.69g sucrose 
 





2.3.2 Leahy Lab Cloning Protocol – Bailey Lab Multi-site Mutagenesis 
 
1. Assemble mixture in the given order 
     [Final]   Control 
dH2O      to 25 uLs  to 25 uLs 
10x Taq Ligase Buffer  1x   1x 
ATP (@ pH ~7.0)   2 mM   - 
dNTPs     1 mM each  - 
Gel purified primers (1-5)  0.2 uM each  - 
Template DNA   ~ 100 ng  ~ 100 ng  
Pfu Ultra DNA polymerase  1 uL   - 
NEB Taq ligase   1 uL   - 
NEB T4 Polynucleotide kinase 1 uL   - 
    Total  25 uL   25 uL 
 
2. Add 1 uL of NEB DpnI directly to the mixture and incubate the reaction for 4-6 hours 
@ 37C (O/N if convenient) 
3.  Transform 5 uL of the digested DNA into E. coli 
4.  Next day-Grow 2-3 colonies and test digest/colony PCR to make sure that your entire 
gene is intact. Because this protocol uses primers that anneal on a single (same) template 
strand, I have found that in case of some of the colonies, the plasmids are truncated (and 
usually your gene is truncated). So I make sure the digestion products from my test 
digests look identical to results I expect in case of the template DNA. 
5. If my test digestions make sense, I send 2 samples for sequencing.  
6. When I use 5 primers (for 5 mutations), I usually find 4-5 of the sites mutated 
(different combinations of sites mutated in DNA from different colonies). 
 
Bailey Lab observations 
1. I get better results (higher number of colonies in my mutagenesis plate compared 
to my control plate) when I gel purify each of the primers (Denaturing UREA gel) 
2. I get more colonies when I do the mutagenesis with shorter plasmids (overall 




2.3.3 Leahy Lab Cloning Protocol – Around-the-Horn Cloning 
 
Protocol from Tim Blower, Berger Lab. 





Each primer should be ~18bp OF COMPLIMENTARY SEQUENCE** 
DON’T use a Taq polymerase, Pfu Ultra works well. 
THE MORE DNA GOING INTO THE LIGATION THE BETTER, so if no colonies 
after first  round try running multiple of PCR rxn and purifying into 16uL *** 
 
1. Primer Phosphorylation 
Perform the following reaction separately for each primer. 
 Reaction Mixture: 
 5uL PNK (T4 polynucleotide kinase, NEB) buffer 
 0.5uL 100uM MgSO4 
 2.5uL primer at 200uM (final concentration = 10uM) 
 1uL ATP at 200mM, pH 7.5 
 1uL PNK 
 dH2O to 50uL final volume 
Incubate reaction at 37 oC for 1 hour, heat kill the PNK at 95 oC for 5 minutes. 
 
2. Site-directed Mutagenesis 
Using pretreated primer mixture, set up the following reaction 
 Reaction mixture:      PCR Program 
 5uL 10x reaction buffer     1. 95oC – 1 minute 
 2.5uL pretreated primer 1 reaction (at 10uM)  2. 95 oC – 30 seconds 
 2.5uL pretreated primer 2 reaction (at 10uM)  3. 55 oC – 30 seconds 
 5uL dNTPs (at 2 - 5mM)      4. 68 oC – (30 sec/kb) 
 2uL template DNA     5. Repeat steps 2 – 4 x 25 
 1uL Ultra II Pfu      6. 68 oC – 5 minutes 
 dH2O to 50uL final volume    12
 oC – hold 
 
** PFU ULTRA II SAYS 15s/KB BUT TIM THINKS 30S/KB WORKS BETTER 
After PCR is complete, add 1.5uL DpnI and incubate at 37 oC for 2 hours 
Run products on an agarose gel, gel extract band in ~ 16uL 
 
3. Ligation 
Ligate (using T4 DNA ligase as written elsewhere) either A) at RT for a few hours or 
B) overnight at 16 oC. 




2.3.4 Leahy Lab Cloning Protocol – Using Bacmid for Insect Cell Transfection 
 
Developed by Matthew Ward and Jennifer Kavran, typed by Lily Raines 
Modified from Invitrogen Bac-to-Bac manual (Version E, Jan 19 2009) 
 
Bacmid Transformation 
Use Kanamycin (50ug/mL) + Gentamicin (7ug/mL) + Tetracycline (10ug/mL) plates. 
Before use, add: 
 50uL of 40mg/mL XGal in DMSO 
 5uL of 40mg/mL IPTG in water 
1. Add 1uL plasmid to 90uL DH10Bac 
2. Incubate 30 mins on ice 
3. Heat shock at 42 oC for 30 seconds 
4. 2 minutes on ice, then add 1mL LB and outgrow at 37 oC for 4 hours (vs. typical 1 
hour) 
5. Spin cells down, resuspend in LB and plate ~200uL 
6. Grow at 37 oC for two days 
7. Pick white colonies. 
 
For bacmid purification, grow white colonies in 5mL of Kan + Gen + Tet at 37 oC O/N 
Notes: Kan stock – 1000x; Gentamicin stock stored at RT – 10mg/mL; Tet stock -20 
covered – 4mg/mL 




 100% isopropanol – 700uL /rxn 
 70% ethanol – 700uL + /rxn 
 TE buffer (miniprep kits) – 50-100 uL/rxn 
 Standard miniprep kit buffers, all standard volumes, or: 
 Resuspension Buffer – 15mM Tris-Cl pH 8.0, 10mM EDTA, 100ug/mL 
RNaseA 
 Lysis Buffer – 0.2M NaOH, 1% (w/v) SDS 
 Precipitation Buffer – 3M KCH3COO (potassium acetate) pH 5.5 
 
1. Pick a white colony, grow O/N in 5mL of Kan + Gen + Tet at 37 oC 
2. Spin down cells, 5000 rpm for 5 mins, decant media and keep cell pellet 
3. Resuspend in 250uL resuspension buffer 
4. Add 250uL lysis buffer, mix by swirling, incubate at RT for 5 mins 
5. Add 250uL precipitation buffer, mix by swirling 
6. Transfer rxn to 1.5mL Eppendorf tube 
7. Spin 14000 rpm x 10 mins at 4 oC 
8. Transfer supernatant to FRESH 1.5mL tube, discard white pellet (avoid transferring 
precipitate) 




10. Spin 14000 rpm x 10 mins at 4 oC 
11. Decant supernatant gently, retain pellet 
12. Wash with 700uL 70% ethanol 
13. Spin 14000 rpm x 10 mins at 4 oC 
14. Decant sup gently. *Multiple ethanol washes are encouraged but not necessary* 
15. Air dry pellet in tissue culture hood for at least 20 minutes 
16. Resuspend pellet in 50 – 100uL TE buffer 
 
Bacmid Transfections into Sf9 Cells 
1. Plate Sf9 cells at 0.8 x 106 cells/mL 
(wait at least an hour to proceed) 
2. Change media in plates to plating media 
 [1.5mL supplemented Grace’s media + 10% FBS] + [8.5mL 
unsupplemented/basal Grace’s media] 
  Note: Graces un/supplemented media and plating media should be 
prepared and stored   in 50mL aliquots. Need 12mL of media per plate. 
3. For each well to be transfected: 
 Add 2uL of 10x DNA to 100uL of Grace unsupplemented media.  
 Add 8uL of Cellfectin II to 100uL of Grace unsupplemented media.  
4. Mix the DNA and Cellfection solutions together, set for 30 minutes at RT 
5. Add mixture to cells 
6. After 4 hours, change media to ISFM (insect serum free complete media) 
 Can be Leahy Lab ISFM or Sf93, insectagrow, Grace sup + 10% FBS 
7. After 3 days, look for infection 
 
Baculovirus Amplification and Expression in Sf9 
1. Produce P1 
 Day 1 – transfect as above 
 Day 2 – x 
 Day 3 – Harvest P1 of virus 
  Decant media, add 2% FBS to store media + virus. Dispose of plated Sf9 
cells 
2. Produce P2 
 Day 1 – Add 0.5mL P1 to 25mL of Sf9 cells at 1.5x106 cells/mL in a T-75 flask  
 Day 2 – x 
 Day 3 – Harvest P2 of virus 
  Decant media, add 2% FBS to store media + virus. Dispose of Sf9 cells 
  Note: assume titer of 3x106 gives an MOI (multiplicity of infection) of 0.1 
2. Produce P3 
 Day 1 – Add 5mL P2 to 250mL of Sf9 cells at 2.2x106 cells/mL in small spinner 
flask  
 Day 2 – x 
 Day 3 – Harvest P3 of virus 
  Decant media, add 2% FBS to store media + virus. Dispose of Sf9 cells 
  Note: assume titer of 5.5x106 gives an MOI of 0.1 
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> Innoculum required, in mL = [MOI x (number of cells)]/titer – we don’t do the plaque 
assay 
  Titer ~=1x106 – 1x107 – 1x108 
  MOI: use 0.05 – 0.1 for virus; 1 – 5 for protein expression. Test 0.5, 1, 2,  
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Maintain Sf9 cells 
- Grow in Leahy Lab ISFM + PenStrep (dilute as directed, not at half strength per 
manual) 
- Split cells at ~2x106/mL, split back to 0.1 – 0.5x106/mL 
- Ideally keep spinner flasks at half volume marked on sides, can go up too 
(necessary for larger flasks) 
- After ~P40, thaw new cells 
-  
To set up large spinners for aeration 
- Take rounded blue aeration set up (blue, about smart phone sized) connect its thin 
tubing to black regulator 
- Connect larger diameter tub to metal rods within larger flasks, add yellow rimmed 
filters to other end 
- Connect filter to thin aeration tubing 
 Large flask metal rod + thicker tubing + filter + small section thin tubing + 
black regulator  + thin tubing from blue aeration tool. 
- Extra tubing, filters, and regulators should all be in insect room. Additional filters 
near tissue culture microscope, they are not reusable. 
 
To clean spinners 
- Run distilled water through flask for 5 minutes (or rinse three times, not 
preferred) 
- Add 10% bleach to flask, disassemble impellers in larger flasks. Let sit 1 hour or 
O/N. 
 *only leave metal tube in larger flasks in bleach for 1 hour* 
- If scum is present on sides of flasks, use scrub brush to remove 
- Run distilled water through flask for 5 minutes (or rinse three times) 
- Use aluminum foil to cover openings, loosen caps, and autoclave once (30min 
sterilze + 25 dry) 
- Close lids and let cool in insect room on shelves 
 
Notes 
- Store all media at 4oC and protect from light 
- If working with secreted proteins, add 0.5 – 2% FBS to media during Sf9 growths 
- Innoculum required, in mL = [MOI x (number of cells)]/titer – we don’t do the 
plaque assay 
  Titer ~=1x106 – 1x107 – 1x108 
  MOI: use 0.05 – 0.1 for virus; 1 – 5 for protein expression 
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- Weiqiang Li had luck using just ISFM through whole process (small scale 
transfection etc), need to confirm 
- Yana Li has insect cells kept in commercial media, passage 4x through ours to 
adapt 
- Spinners under 125mL volume do not aerate well, don’t use. Use multiple flasks 
instead. 
- Spinners don’t stay sterile for a long time, if it’s been a while autoclave before 
use. 
- Sf9 cultures won’t exceed 2x106/mL in smaller spinners, can reach 4 - 5x106/mL 






2.2 General Nanodisc Packaging Protocol 
 




1. Expect half of protein to precipitate during packaging step – plan accordingly for 
downstream applications 
2. Protocol produces ~10% packaged discs to reduce formation of multiply packed discs, 
do not increase relative proteins amounts. 
 
General Packaging 
1. Form lipid film on interior of disposable glass culture tube by drying lipid stock 
solution in chloroform  under gas (air/N2), then under high vacuum O/N to remove 
residual chloroform. 
2. Resuspend lipid in cholate/TrisHCl/NaCl/EDTA solution, form lipid-detergent 
micelles 
3. Add membrane scaffold protein (MSP) to desired MSP:lipid ratio. Add protein to 
incorporate if desired. 
4. Incubate lipid/cholate/protein for 15 – 60 minutes at 4oC. 
5. Remove detergent with adsorbent beads (BioRad BioBeads) overnight at 4oC.  
 Note: For 100uL reactions, use a minimum 25mg biobeads [500mg/2mL 
reaction] 
6. Remove beads from solution, filter solution with 0.45µm filter,  
7. If desired, separate packaged and empty discs using on gel filtration  
 
Lipid Film Formation 
Dry 30uL of 25mM stock of lipids in chloroform (0.75 µmoles lipid) 
 Note: only need about 5uL per reaction, but that’s too small a volume for me to 
 measure accurately 
Resuspend with 7.5uL 200mM cholate (1.5 µmoles cholate) and 262.5µL MSP buffer  
 Note: final volume 270uL, enough for ~ 6 tEGFR reactions 
 
EGFR/Nano packaging 
7.5x10-4 µmoles scaffold protein (MSP) 
43.4uL lipid resuspension 
10ug EGFR (7. 5x10-5 µmoles) 
MSP buffer to 100uL reaction volume 
[EGFR] = 0.1mg/mL 
 
References 
Ritchie TK, et al. Chapter 11 - Reconstitution of membrane proteins in phospholipid 
bilayer nanodiscs. Methods Enzymol. 2009;464:211-31. 
Mi LZ, et al. Functional and structural stability of the epidermal growth factor receptor in 
detergent micelles and phospholipid nanodiscs. Biochemistry. 2008 Sep 
30;47(39):10314-23. Epub 2008 Sep 5. 
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2.3 Heterodimer Purification Protocol 
 
Developed by Lily Raines 
Approximate Time to Completion: 2 weeks 
Approximate Yield: 100 – 200ug/2L cells (ErbB2/3) 
All purification steps, aside from filtering, performed at 4oC 
 
1. Transiently transfect mammalian cells in suspension, using 200ug of maxiprepped 
DNA/L of cells with 600ug of PEI. 
2. Next day, split cells back 1:3 in hybridoma media + 0.5% FBS 
3. Harvest media with 1000g x 5min spin at 4oC 
4. Sterile filter media w/ 0.22um filters,  
 Note: Add 0.5M sodium azide to 1mM if purification does not begin immediately. 
 Stocks above 0.5M sodium azide cannot be disposed of down the sink – do not 
make. 
5. Use the centramate to concentrate media and buffer exchange into buffer A 
 Buffer A: 20mM Tris pH 8, 1M NaCl 
6. Equilibrate 5mL of nickel resin with buffer A, allow to batch bind concentrated media 
overnight with stirring. 
- - - 
7. Apply resin and media to a gravity column, collect flow-through 
8. Wash resin with 10 column volumes (CV)/50mL of 
 i. Buffer A + 1M Urea 
 ii. Buffer A + 0.75% TX-100 
 iii. Buffer A + 1M Urea 
 iv. Buffer A + 0.75% TX-100 
 v. 100mL of buffer A 
8. Elute resin with 60mL buffer A + 250mM imidazole 
 Optional: confirm elution on SDS-PAGE – do first run, not necessary thereafter 
9. Dilute eluate to 1L with buffer A, 
10. Equilibrate 5mL of nickel resin with buffer A, allow to batch bind diluted eluate 
overnight with stirring. 
- - - 
11. Apply resin and media to a gravity column, collect flow-through 
12. Wash with 300mL of buffer A 
13. Elute with 60mL buffer A + 250mM imidazole, collecting 5mL fractions 
14. Run SDS-PAGE gel to determine which fractions contain heterodimer 
- - - 
15. Pool fractions containing heterodimer 
 To detag: add excess PreScission (1-2mL Leahy Lab stock) 
 To deglycosylate: add 1mL PNGaseF (Leahy Lab stock) 
16. Dialyze sample for two nights against 4L of 20mM Tris 7, 150mM NaCl, 1mM 
EDTA 
17. To prepare for “reverse nickel,” dialyze sample against 4L of 20mM Tris 8, 150mM 
NaCl for at least one hour 
18. Equilibrate Ni-HiTrap 5mL column on Akta with 20mM Tris 8, 150mM NaCl 
102 
 
19. Spin sample at maximum speed for 15 minutes before loading onto Akta 
 Note: you will probably need to transfer your solution to a fresh tube and spin at 
least  one more time to remove all precipitate. 
20. Collect flow-through 
21. Wash with 5 CV (25mL) of 10% elution buffer - buffer A + 250mM imidazole 
22. Elute column with 10 CV of buffer A + 250mM imidazole, collecting 5mL fractions 
23. Run a gel and pool heterodimer containing fractions and flow-through 
 WILL have some in elution fractions 
24. Dialyze overnight against 4L of 20mM Tris 8, 50mM NaCl 
- - - 
25. Clean and equilibrate 5mL HiTrap Q column with 20mM Tris 8, 50mM NaCl 
26. Spin dialyzed sample and apply to Q column 
27. Collect 5mL fractions and elute using buffer A 
28. Run a gel to determine which fractions contain heterodimer 
- - - 
29. Concentrate heterodimer containing fractions to <15mL 
30. Equilibrate S200 26/60 gel filtration column in 5mM Tris 7.5, 150mM NaCl 
 Note: This takes 3-4 hours and can be done overnight 
30. Spin and load sample onto S200 column 
31. Run a gel to determine which fractions contain heterodimer 




2.4 Centramate Care and Use Protocol 
 
Important Notes 
1. NEVER fully close the retentate valve 
2. NEVER touch the middle of the filter 
3. NEVER start a run without finishing the run in the same 4 hour period. 
4. NEVER run the centramate unattended after introducing your sample  
5. The tubing used on this system is prone to breaking within the peristaltic pump; each 
~6”section  may only be used for 2 sample runs. Use fresh or 1x used tubing for your 
sample run, and mark  your used section of tubing after use. 
6. DO NOT leave the apparatus fully assembled unless you are 100% CERTAIN it will 
be used in  the next two days. 
7. Your sample and all buffers MUST be filtered through a 0.2 um filter. 
8. Molecular weight cut-off for the filter is 30kDa, make sure the MW of your protein is 
above this. 




16L water (re-filling two 4L buckets as necessary works well) 
1L (at least) of the buffer you’d like to exchange into. 
1L 0.5M NaOH 
1L 0.1M NaOH 
0.2um filtered sample 
A timer 
 
NWP Test Protocol 
NWP: Normalized Water Permeability 
TMP: Transmembrane Pressure 
 [(Pressure Left Front and Back)/2] - (Pressure Right Waste Valve) 
 
1. Pump system into air, setting 200 (~1.2L/min flow) 
2. Introduce distilled water to system, both valves open, run until no more bubbles seen in 
lines 
3. Purge 3 times 
 To purge: while running water, tighten retentate valve (left back) briefly until 
 pressure rises to ~20psi. Immediately release, repeat 3x or until no more air 
 bubbles are seen. 
4. Record outlet flow over 30 seconds noting pressure on left valves 
5. Pause system, tighten retentate (left back) valve slightly until pressure increases, never 
 going above 60psi total pressure for front and back (inlet and retentate) valves. 
6. Adjust TMP and collect a total of three flow rates at TMP ranging between 15 and 
 30psi 
7. Record TMP and Flow Rates in provided table. Plot approximate data. 
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8. System is ready for use if NWP test results over three TMP values are between first 
 use (maximum for filter) and first drop (dramatic drop seen after initial filter run) 
 lines. 
 
Concentration and Diafiltration Protocol 
1. Assemble Apparatus 
Note: Only touch the sides of the filter and NEVER the middle 
Note: If you match the orientation of holes in the gasket, you will place the filter in the 
correct orientation. 
 a. Remove gasket from 0.1M NaOH storage solution, place onto centramate  
 system.  
 b. Add filter, then sandwich with remaining gasket.  
 c. Top with metal plate.  
 d. On each of the 4 protruding screws, add a longer metal rod, a shorter metal rod, 
 a washer, and a hex nut. 
 e. Use a torque wrench to fasten the metal plate. Confirm that this wrench is set to 
 70psi and is in the ‘on’ position. DO NOT tighten one screw completely and then 
 complete the others. Tighten one screw slightly, then the screw directly across 
 from it, etc, until torque wrench ‘breaks’ while tightening. This will prevent you 
 from over-tightening the system. 
 f. Feed inlet tubing through peristaltic pump. Make sure tubing is placed in  
 tightly. Confirm that  pump speed is set to 200. This corresponds to ~1.2L/min 
 flow out of the pump, which will translate to 0.5L/min off the filter. 
2. Pump System into air 
3. Rinse System into water 
 a. Run water through system until no bubbles are seen 
 b. Purge valves (same as with NWP test) 
 c. Run 8L of water through the system, do not recirculate (do not place retentate  
 and permeate tubing in feed vessel). 
4. Perform NWP Test (see earlier protocol) 
5. Rinse System into 1L PBS  
 a. Run PBS through system for 30 seconds, without collecting retentate or  
 permeate 
 b. Recirculate (place inlet, retentate, and permeate tubing in same feed vessel) 
 remaining PBS for 10 minutes. 
 
5. Concentrate Media 
*After starting this step, DO NOT LEAVE DEVICE UNATTENDED  
until sample is harvested* 
 a. Place inlet and retentate tube in feed vessel with media. 
 b. Start pump, proceed ‘as low as you can go’, until no more media can be taken 
 up without introducing air into the system 
NOTE: you MAY pause the pump briefly during this process (steps 5-7), but only to add 





6. Diafiltrate  
 a. Pause pump, add new buffer to concentrated sample.  
 b. Restart pump with inlet and retentate tubing in same feed vessel.  
 c. Diafiltration with 1L (10 x dead volume) will result in >96.8% buffer exchange. 
7. Harvest  
 a. Close permeate valve, keep retentate valve fully open 
 b. Pump system into air and collect retentate 
Note: if your protein is especially sensitive you can harvest with PBS, but this will limit 
your final volume. 
 
8. Rinse system into 1L PBS and recirculate  
 a. As in step (3), run PBS through system until no bubbles are observed, purge 
 valves (unless  already did this with additional buffer chase) 
 b. Recirculate (inlet, retentate, and permeate tubing in same feed vessel) for 10 
 minutes. 
9. Rinse system with 8L of water without recirculating 
10. Recirculate 1L 0.5M NaOH in system for 30 minutes  
 a. Let 0.5M NaOH run through system for ~10sec before starting recirculation to 
 flush out residual water 
 
11. Storage 
 If less than two days before next use:  
  Introduce 0.1M NaOH to the system. Ensure no bubbles are present, store  
  retentate, permeate, and inlet tubing in feed vessel. 
 If more than two days:  
  Run system into 0.1M NaOH, then into air. Disassemble filter, turning  
  torque wrench to the ‘off’ position, store in provided airtight container of  
  0.1M NaOH (if debris noticed in storage solution, replace 0.1M NaOH).  
  Loosen all gauges and joints. Flip torque wrench back to ‘on’ position and 




2.5 Monthly AKTA Maintenance Protocol 
 
Developed by Jennifer Kavran, typed by Lily Raines 
 
Once a month, perform the following maintenance on all AKTA’s 
 
1. Wash both pumps into 1M NaOH 
2. Run NaOH through system, set to 50% B to flow through both pumps, for 30 minutes 
at 1 mL/min 
3. Microwave approximately 1L of MilliQ water for 15 minutes 
4. Pump wash into hot MilliQ, run water through both pumps for at least 30 minutes at 
5mL/min 
5. Check pH of waste – if neutral, proceed 
6. Change 20%  ethanol at pump seals 
 - at AKTA Pure, in a 50mL conical tub at bottom right of instrument. Change 
tube itself if grimy 
 - at other AKTA, ethanol is in a square plastic bottle. Be gentle with four inlet 
 tubes (two per pump) while re-filling, cover with parafilm 
  
* tubing becomes fragile and can break over time. If tubing does break, order 
replacement from GE. Expect 2 – 3 days for it to arrive 
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